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Abstract 
Background: Following national and regional recommendations, intravenous lipid emulsion 
(ILE) has become established in clinical practice as a treatment for acute local anesthetic (LA) 
toxicity, although evidence of efficacy is limited to animal studies and human case reports. A 
lipid emulsion workgroup was therefore established by the American Academy of Clinical 
Toxicology to review the evidence on the efficacy of ILE for LA toxicity. 
Methods: We performed a systematic review of the literature published through December 15th 
2014. Relevant articles were determined based on predefined inclusion and exclusion criteria. 
Pre-treatment experiments, pharmacokinetic studies not involving toxicity and studies that did 
not address antidotal use of ILE were excluded. 
Results: We included 113 studies and reports. Of these, 75 were human and 38 animal studies. 
One publication included both a human case report and an animal study. Human studies included 
one randomized controlled crossover trial involving 16 healthy volunteers. The subclinical LA 
toxicity design did not show a difference in effects of ILE versus saline. There was one case 
series and 73 case reports of ILE use in the context of toxicity (83 patients) including CNS 
depression or agitation (n=45, 54%), seizures (n=49, 59%), hypotension, hypertension, EKG 
changes, arrhythmias (n=39, 47%), cardiac arrest (n=18, 22%), cardiopulmonary resuscitation 
and/or requirement for endotracheal intubation and/or mechanical ventilation  (n=35,42%). There 
were 81 (98%) survivors including 63 (76%) with no reported sequelae from the LA poisoning or 
ILE, although the presence or absence of sequelae was not reported in 15 (18%) cases.  
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Animal studies included 29 randomized controlled studies, 3 observational studies, 5 case series 
and one case report; bupivacaine was used in 29 of these reports (76%). Of 14 controlled 
experiments in animals, 8 showed improved survival or time to return of spontaneous circulation 
and 5 no benefit of ILE versus saline or non-ILE treatments. Combining ILE with epinephrine 
improved survival in 5 of the 6 controlled animal experiments that studied this intervention. The 
studies were heterogeneous in the formulations and doses of ILE used as well as the doses of LA. 
The body of the literature identified by this systematic review yielded only a very low quality of 
evidence. 
Conclusion: ILE appears to be effective for reversal of cardiovascular or neurological features in 
some cases of LA toxicity, but there is currently no convincing evidence showing that ILE is 
more effective than vasopressors or to indicate which treatment should be instituted as first line 
therapy in severe LA toxicity. 
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Introduction 
There has been increasing interest in the use of intravenous lipid emulsion (ILE) for the treatment 
of acute local anesthetic (LA) poisoning following the publication of a case report in 2006.(1) 
Since then, national and regional anesthesiology societies have published recommendations for 
use of ILE in the treatment of LA toxicity after iatrogenic overdose.(2-4) However, evidence 
supporting the use of ILE in the context of toxicity involving local anesthetics or other toxins has 
been reported by previous reviews to consist primarily of human case reports and controlled 
animal experiments that cannot necessarily be extrapolated to human clinical settings.(5-8)  
 
The American Academy of Clinical Toxicology (AACT) therefore created a Lipid Emulsion 
workgroup, which included clinical experts in clinical toxicology, anesthesiology, emergency 
medicine, critical care, and pharmacy with assistance of medical librarians and epidemiologists. 
This workgroup was tasked to review all appropriate evidence pertaining to the use of lipid 
emulsion in toxicology, with the ultimate goal of providing a comprehensive evaluation of the 
published evidence and consensus-based recommendations.(9) Here we present the results of our 
systematic review of human and animal studies regarding the effect of ILE in the treatment of LA 
toxicity. Use for treating toxicity from other substances and adverse effects of ILE will be 
presented in other systematic reviews. 
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Methods 
A working subgroup (the authors) of the American Academy of Clinical Toxicology 
lipid emulsion therapy workgroup (9) was formed to gather and review the evidence 
on the effect of ILE in the treatment of LA toxicity.  This subgroup was formed 
based on the best possible match to represent the clinical experts and various 
stakeholders and involved in the workgroup. It also included two medical librarians 
who assisted in conducting the systematic searches and the retrieval of potentially 
eligible publications, as well as an epidemiologist with specific methodological 
expertise in conducting systematic reviews. Subgroup members divulged all potential 
conflicts of interests prior to inclusion in the workgroup. All communication was 
performed by email exchanges and by telephone conferences.  
 
Two medical librarians created a systematic search strategy for Medline (Ovid), which is 
provided at Appendix 1.  The strategy comprised a combination of Medical Subject Headings, 
title/abstract key words, truncations, and Boolean operators, and included the concepts of ILE 
and toxicology (including but not limited to local anesthetics). It was subsequently translated for 
Embase (via Ovid), CINAHL (via EBSCO), BIOSIS Previews (via Ovid), Web of Science, 
Scopus, and the Cochrane Library/DARE.  All databases were searched from inception to 
December 15th 2014.  
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In addition, conference abstracts from the European Association for Poison Centres and Clinical 
Toxicologists, and the North American Congress of Clinical Toxicology (both from 2000 to 
2014) and previous reviews were hand-searched by various group members. Abstracts from the 
Asia Pacific Association of Medical Toxicology were searched in the same way from 2007 to 
2014. Group members also performed cross-referencing of full-text articles. No limits were 
applied for language, and candidate studies in languages not known to any of the authors were 
translated. 
 
In summary, the criteria for publication inclusion in the evaluation of the effect of ILE include 
studies in humans and animals to whom ILE was given for the purpose of treating poisoning, and 
exclusion criteria are non-original data, animal studies with methods and results that cannot be 
extrapolated or are uninterpretable to humans, pre-treatment models, and experimental in vitro or 
ex vivo models. A complete methodology of the larger project of which this systematic review is 
one part has been previously published, and describes in detail all relevant methodological 
aspects such as clinical questions, search strategies, eligibility of publications, data extraction and 
summary, and assessment of the risk of bias (9). 
 
The log D, which is based on the partition coefficient, and is a measure of lipophilicity, is 
reported for each local anesthetic. The degree of lipophilicity directly corresponds with the log D; 
as the log D increases, so does the lipophilicity of a substance. 
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Results 
Our combined search for the effect of ILE retrieved 838 full text articles  that were subsequently 
analyzed for their pertinence to LA. Of these, 113 publications were included in our systematic 
review. Among the included publications, 75 were conducted in a human setting and 38 in an 
animal setting. One article included both a case report and an animal experiment. One human 
study was published as two publications. The flow diagram of study selection is presented in 
figure 1.  
 
Human studies 
 
Randomized controlled trials  
One phase-II randomized controlled trial (unpublished, available as conference abstract at the 
time of writing) evaluated the efficacy of ILE on the pharmacokinetic properties of LA in 16 
healthy volunteers (8 female and 8 male) aged 18-40 years (Table 1).(10, 11) This was a double-
blind crossover study consisting of a first phase of habituation to LA with an infusion of 
lidocaine, followed by a second phase of either a continuous infusion of ropivacaine or 
levobupivacaine at 8 mg/min treated with either a bolus of 120mL of 20% ILE or of 0.9% saline, 
administered two minutes after the start of the LA infusion. The primary outcome of interest was 
the duration of drug infusion (expressed as total dose) required to induce early clinical signs of 
neurotoxicity such as paresthesiae and a sensation of inebriation, as evaluated by an examiner 
blinded to the treatment.  Secondary outcome measures were detection of sub-clinical seizure 
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activity based on electroencephalogram (EEG), duration of PR, QRS intervals based on 
electrocardiogram (EKG) and pharmacokinetics of local anesthetics (maximum concentration 
(Cmax) and area under the plasma concentration versus time curve (AUC)).  
No significant difference in the total LA dose given to reach early signs of clinical toxicity was 
observed between ILE and control groups: Ropivacaine/ILE (75.7 mg ± 29.1 mg) or saline (81.7 
mg ± 22.3 mg) and Levobupivacaine/ILE (69.4 mg ± 26.2 mg) or saline (80.8 mg ± 31.7 mg) (p 
= 0,61). The LA dose was provided at 8 mg/min, and maximum allowed dose was 120 mg. Four 
of the 16 volunteers received the maximum dose of LA allowed in the protocol. No EEG 
abnormalities were seen. QRS prolongation was present at the end of the LA infusion as 
compared  to baseline (P < 0.001),  but no significant difference  was observed between the ILE 
and control groups (p= 0.68).(11) Small pharmacokinetic differences between groups, including a 
25-30% reduction in Cmax and a 20% increase in volume of distribution of the LA at a 
comparable mean dose, were not statistically significant and disappeared after 45 minutes.(10) 
The authors concluded that their study confirmed the lipid sink hypothesis in humans, but that no 
clinical efficacy of ILE could be observed in this systemic toxicity model, where a 3.8 msec 
prolongation in QRS was induced by the LA perfusion. No obvious risk of bias was identified 
from the research protocol 
(https://clinicaltrials.gov/ct2/show/NCT01602250?term=toxalip&rank=1), but concerns remain 
regarding indirectness (use of surrogate markers and uncertain generalizability to a poisoning 
context) and imprecision of the reported results due to the small sample size (potentially 
underpowered study).  
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No published peer-reviewed clinical controlled or observational studies were retrieved by our 
search.  
 
Human case reports 
There were 73 case reports and one case series, including 10 cases not individually reported 
elsewhere, that described the effect of ILE for treating LA toxicity.(1, 12-84)  These articles 
involved 83 patients, aged from 2 days to 91 years, of whom two died and 81 (98%) survived 
(Table 1). The local anesthetics involved, often in combination, are shown in Tables 1 and 2. 
 
The most common lipid concentration administered in these publications was 20 % (71 cases; 
86%), while a 10% concentration was used in one case,(35) and the lipid concentration used was 
not reported in the remaining 11 cases (Table 1).(17, 19, 23, 28, 40, 47, 51, 71) Lipid emulsion 
was administered as a bolus in 30 (36%) cases, as a bolus followed by infusion in 34 (41%) 
cases, and as an infusion without bolus in 8 cases (10%). The dose regimen used was not 
specified or not reported in 11 (13%) cases. The median bolus dose was 0.30 g/kg (range 0.0015-
0.83 g/kg) and the median infusion dose was 1.9 g/kg/hr (range 0.015-6.0 g/kg/hr).  Overall, the 
total volume of lipid emulsion administered ranged from 9 mL to 2,480 mL (Table 1). The bolus 
dose in infants up to the age of one year was 1-2 mg/kg (Table 1).  
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In 52 cases (63%) the lipid emulsion used was Intralipid™; Other formulations used were 
Medialipid™ (n=3, 4%), Lipofundin™ (n=3, 4%), Liposyn™ (n=2, 2%), Lipovenoes™ (n=1, 
1%), Kabiven™ (n=1,1%), and Intralipos™ (n=1, 1%). In 20 (24%) cases the lipid emulsion 
formulation was not reported (Table 1). 
 
Sixty-nine (83%) patients experienced toxicity following the use of local anesthetics for nerve 
blocks (Table 1), including 10 cases described in the single case series (Table 1).(19) Toxicity 
was also reported after intravenous (n=4; 5%),(25, 32, 51, 74) subcutaneous (n=6; 7%),(12, 19, 
29, 33, 44, 54) intraosseous (n=1; 1%),(31) topical (n=1; 1%),(45) intraperitoneal (n=2; 2%),(44, 
65) intraarticular (n=1; 1%),(29) and intrapleural administration (n=1; 1%)(39). Two routes of 
administration were involved in three cases (4%)(29, 44, 65) and the route was not reported in 
one case (1%)(40) (Table 1). 
 
The most frequent toxic effects from LA reported were central nervous system (CNS) features 
including (but not limited to) CNS depression/coma or agitation (n=45; 54%) and seizures (n=49; 
59%). Cardiovascular features included hypotension, hypertension, EKG changes and 
arrhythmias (n=39; 47%) and cardiac arrest (n=18; 22%); other non-cardiovascular symptoms 
(n=22; 27%) were also common (Table 1).  
 
In 14 cases (17%),(21, 35, 37, 42, 44, 46, 48, 51, 52, 61, 63, 65, 74, 80) ILE was the only 
treatment used for reversal of toxic effects and in 10 (12%) of these resolution of symptoms was 
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reported.(21, 35, 42, 44, 46, 48, 52, 61, 65, 74) In 4 (5%) cases the authors reported that it was 
unclear if effects were related to ILE.(37, 51, 63, 80) One case report did not comment on ILE 
effects (46) (Table 1).  
 
Sixty case reports (72%) described the use of ILE in combination with additional treatments. In 
35 (42%) cases lipid emulsion was used after failure of other treatments, in 6 (7%) cases before 
other treatment, and in 16 (19%) cases lipid emulsion was used concomitantly. The sequence of 
treatment was not reported in 3 (4%) cases (Table 1). 
 
Other treatments used included benzodiazepines or other sedatives (n=41; 49%), vasopressors 
(n=29; 35%), sodium bicarbonate (n=7; 8%), antiarrhythmic drugs (n=9; 11%), intravenous 
fluids (n=5; 6%), and/or other treatments (n=20; 24%). Three studies (4%) reported other but 
unspecified treatments. Cardiopulmonary resuscitation (CPR) and/or intubation and/or ventilation 
were initiated in 35 (42%) cases. In 3 (4%) cases the patient was already intubated when features 
of LA toxicity appeared. Oxygen supply by mask was initiated in 9 cases (11%). Cardiac 
defibrillation was reported in 4 cases (5%). CPR and/or intubation were not required in 19 (23%) 
cases and use of these procedures was not reported in 16 studies (19%) (Table 1). Nine case 
reports did not state if any other treatments were performed (Table 1). 
 
The authors of these case reports observed that ILE had a possible beneficial effect or was the 
cause of resolution of toxic features in 59 of cases (71%). Four case reports (5%) suggested no 
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benefit from ILE. In 10 case reports (12%) it was unclear whether benefits were related to ILE or 
not; the effect of ILE was not described in 10 other cases (12%) (Table 1). 
 
Animal studies 
Among the 38 publications using animal models, 29 (76%) were randomized controlled studies 
(11 studies on rats, 14 on pigs, 2 on dogs, and 2 on rabbits)(17, 85-112), 3 (8%) were 
observational studies (1 study on pigs, 1 on rats, 1 on rabbits)(113-115), 5 (13%) were case series 
(1 study on rabbits and 4 on rats)(116-120) and one (3%) was a case report (cat)(121). The 
animal studies are summarized in Table 3.  
 
The local anesthetics studied the 38 studies included bupivacaine (n=29 studies, 76%) 
levobupivacaine (n=5, 13%), lidocaine (n=1, 3%), mepivacaine (n=1, 3%) and ropivacaine (n=4, 
11%). Two studies combined two local anesthetics, bupivacaine/mepivacaine and 
levobupivacaine/ropivacaine (Table 3). 
 
Lipid concentrations used were 20 % (n=22, 58%), 30 % (n=8, 21%) or not described (n=2, 5%). 
A bolus dose was used in 29 (76%) studies and was followed by an infusion in 22 (58%) studies. 
In three (8%) studies an infusion was used without an initial bolus. The median bolus dose was 
0.80 g/kg or 4mL/kg of 20% ILE (range 0.20-3.0 g/kg) and median infusion dose was 6.0 g/kg/hr 
(range 0.60-54 g/kg/hr). In 22 (58%) studies, the lipid emulsion used was Intralipid™ while two 
studies used the medium chain/long chain triglyceride preparations Lipovenos™ MCT (n=2/ 5%) 
14 
AACT manuscript LA to edit for CTX 
 
 
or Medialipid™ (n=1/ 3%). Other products used in one study each (3%) were Lipovenos™, 
Ivelip™, SMOFLipid™, ClinOleic™, and Liposyn II™; an un-named Soybean oil emulsion was 
used in one study and the ILE formulation used was not reported in five studies (Table 3). 
 
Animal randomized controlled studies 
In 12 of the 29 randomized controlled studies, ILE was compared to the vasopressors epinephrine 
and/or vasopressin, either alone or in combination, or with vasopressors combined with ILE 
(Table 3).(88, 89, 91, 92, 97, 102-105, 107, 110, 111)  
 
The ILE vs. epinephrine studies (88, 89, 91, 102-104, 107, 110, 111), showed therapeutic benefit 
on survival or return to spontaneous circulation for ILE compared to epinephrine in four studies 
(14% of the animal RCS) (102-104, 107) and for epinephrine+vasopressin in one study (3% of 
the animal RCS).(105) There were comparable effects of ILE and epinephrine in five studies 
(17% of the animal RCS).(88, 89, 91, 110, 111)  
 
Combining epinephrine+ILE gave a better survival outcome compared to ILE alone in six studies 
(21% of the animal RCS),(88, 89, 97, 102, 104, 111) and of these, two  studies concluded 
comparable effect of epinephrine and epinephrine+ILE.(102, 104)  
 
In two studies (7% of the animal RCS), the combination vasopressin+ILE did not improve 
survival over ILE alone and was not as effective as epinephrine or epinephrine+ILE 
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treatment.(102, 104) ILE was superior in one study (4% of the animal RCS) comparing ILE with 
vasopressin alone or epinephrine+vasopressin.(92) 
 
Lipid infusion was compared to crystalloids, either saline (17, 85-87, 90, 91, 94, 96, 97, 106-111) 
or Ringer’s acetate(101) in 15 of the 29 randomized controlled studies. (Table 3) Nine (31% of 
the animal RCS) studies showed therapeutic benefit (85, 87, 90, 91, 94, 97, 106, 109, 110) and 
six (21%) no benefit if ILE.(17, 86, 96, 101, 107, 111) In one study comparing ILE and saline, 
the control groups were different (electrically initiated ventricular fibrillation vs. LA induced 
venticular fibrillation); this study was therefore considered not useful for evaluating the effect of 
ILE.(108)  
 
Various LA doses were evaluated in the included studies, and these doses were provided in 
varying units. These doses depended on the type of LA and the secondary outcome symptom 
severity. For bupivacaine, used in 22 (76%) out of the 29 studies,(86, 87, 90-97, 100-106, 108-
112) the dose ranged from 1 mg/kg/min to 10 mg/kg given over 10 seconds or 4-30 mg/kg (Table 
3). Levobupivacaine was used in four studies (14%),(88,89, 98,99) with a dose of 500 mg/hr 
(88), 10 mg/kg (99) or 3-8.3 mg/kg/min (89,98). Mepivacaine was used in one study (3%) at an 
infusion rate of 6 mg/kg/min.(101) Ropivacaine was used in three studies (10%),(17, 85, 107) at 
1.5 mg/kg/min as lowest infusion dose up to a maximum of 14.9±2.8 mg/kg given as a bolus 
(Table 3). 
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Resuscitation treatments were generally initiated immediately or within three minutes of the 
termination of LA administration (Table 3). Intravenous lipid emulsion was initiated immediately 
or within one minute in 19 studies (17, 85, 87, 90, 92, 94, 96, 98, 100-104, 106, 110, 116-119) or 
less commonly up to three minutes (2 studies),(97, 105) four minutes (1 study),(86) 10 minutes (2 
studies), (109, 111) or 20 minutes (1 study)(108) after termination of LA administration. The 
timings of administration of study treatments were not reported in three studies (10%).(88, 91, 
107) Three studies (10%) were not designed to evaluate the therapeutic effects of ILE alone, and 
either compared the use of ILE for toxicity caused by two different local anesthetics,(101) 
compared two types of ILE (long-chain triglyceride vs. long-chain and medium-chain triglyceride 
(100) or evaluated the myocardial tissue pH.(108) These studies were not considered 
generalizable to human poisoning and were therefore excluded from further analysis.  
 
Animal observational studies 
The three observational studies included in this review measured the LA dose required to cause 
death in 50% of the animals dosed (LD50),(115) compared the effect of ILE or saline on QRS 
widening using ILE or saline,(113) or compared ILE to hypertonic saline in combination with 
ILE.(114)  
  
Intravenous lipid emulsion was initiated immediately or within two minutes of the termination of 
LA administration (Table 3). Bupivacaine was used at 4 mg/kg (113), 10 mg/kg (114) or at 
several different doses.(115) A benefit of ILE use was supported by the demonstration that lipid 
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infusion increased the bupivacaine LD50 in rats by 48%, from 12.5 to 18.5 mg/kg,(115) and by 
reversing the lengthening of QRS interval induced by the injection of bupivacaine in pigs.(113)  
(Table 3)  
 
Animal case reports and case series 
Only one animal case report was retrieved from our literature search, describing a cat suffering 
from toxicity after administration of lidocaine 140 mg (20 mg/kg).(121) The ILE infusion 
regimen was derived from clinical human studies, but the dose was reduced due to concerns 
about fluid overload. The authors reported a pronounced clinical response within 15 minutes of 
ILE initiation, with the cat becoming more responsive to stimuli and being able to hold its head 
up without assistance.  
 
Five studies were included in this review as case series as the studies did not include a control 
group without ILE or included ILE in both study groups.(116-120) Thus, one study compared 
ILE plus the addition of three different doses of epinephrine,(116) one study compared the effect 
of  ILE for either levobupivacaine or ropivacaine toxicity,(120) and three studies evaluated if the 
protective action of lipid emulsion was mediated through the fatty acid oxidation pathway(117, 
118) or involved the opioid receptor.(119) 
Bupivacaine 10 mg/kg was the LA used in 4 of these 5 studies,(116-119) and levobupivacaine 
and ropivacaine were used in the other study each at a dose of 2 mg/kg/hr.(120) Intravenous lipid 
emulsion was initiated immediately or up to one minute after LA administration. 
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Assessment of the quality of evidence  
Table 4 presents the summary estimates with associated Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) ratings for the 2 human controlled studies 
reporting the effect of ILE on LA cardiotoxicity and neurotoxicity. All other evidence retrieved in 
this systematic review was rated as of very low quality; the human studies were seriously limited 
by their study designs (all uncontrolled studies preventing comparison with a control group, such 
as case series and case reports) and by the high likelihood of publication bias (especially with 
case reports), while animal studies were seriously limited by indirectness (resuscitation model 
lacking generalizability to humans) and imprecision (systematically underpowered studies).(122-
128) 
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Discussion 
In our systematic review on the effect of ILE for acute LA toxicity, we identified animal and 
clinical studies that yielded a very low quality of evidence. Most randomized studies were 
conducted in animal settings with limited observation of test subjects after treatment and where 
no autopsies were performed or drug concentration measured. The human publications presenting 
the effect of ILE in severe LA toxicity were mainly case reports. Data from these studies and 
reports showed inconsistent benefits of ILE for the treatment of acute LA intoxication. Many also 
employed several treatments and, although this reflects what often happens in clinical practice, it 
makes the assessment of the specific effects of ILE difficult if not impossible. 
 
A possible beneficial effect was reported in 71% of the human case reports, although this 
estimate of benefit is questionable due to the high risk of publication bias usually associated with 
this specific study design and due to the indirectness of the results caused by the absence of 
comparison to a control group. Furthermore, the only human controlled study showed no effect of 
ILE on mild LA toxicity. Thus, most of the useful evidence supporting a beneficial effect of ILE 
relies on animal studies. In controlled animal experiments and animal observational studies the 
effects of ILE were mainly based on cardiovascular variables, which are the most frequently 
observed adverse events with bupivacaine, the LA most often studied. Neurological symptoms 
could not be fully evaluated as the animals used were anesthetized during the experimental 
procedures. Results suggested improved efficacy for the reversal of LA cardiovascular toxicity 
with ILE alone compared to other treatments received alone in 48% of the controlled animal 
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studies , but reduced efficacy was seen in 28% of the these studies. The dose of LA given to 
induce toxicity in animals may not be comparable to the toxic dose known in humans and the 
amount of ILE given bolus often exceeded current recommendations.  
 
When ILE was compared to other active treatments (vasopressors), inconsistent results were 
observed. There were 13 controlled animal studies favoring ILE alone, 6 studies favoring 
vasopressors and 7 studies favoring the combination of vasopressors and ILE. These studies are 
too heterogenous to allow a pooled analysis. The limited results of the available observational 
studies also suggested a possible clinical benefit from ILE alone or in combination with other 
resuscitative treatments with the same limitations to the human poisoning context as stated 
previously. 
 
From the 8 animal experiments using vasopressors and ILE, results appears to be conflicting and 
in particular with the use of epinephrine. On the one hand, ILE appears to be associated with 
better hemodynamic outcomes in one study.(110) On the other hand, epinephrine alone, or the 
association of epinephrine and ILE, was better than ILE alone for survival or hemodynamic 
outcomes in five other studies in pigs and rats.(102-104, 107, 111). It is worth noting that the 
amount of epinephrine and ILE given were quite heterogenous and the formulation of ILE was 
not reported in one publication. Finally, two studies demonstrated no differences between 
epinephrine and ILE for mortality.(88, 97) 
 
21 
AACT manuscript LA to edit for CTX 
 
 
Thus, data from the human case reports and the animal studies provides weak evidence that that 
ILE may be effective in some cases of LA toxicity. However, there is no convincing evidence 
that this treatment is more effective than the use of vasopressors. These results also do not offer 
evidence to support which treatment should be instituted as first line therapy when cardiovascular 
toxicity arises after LA anesthetic administration. 
 
 
Limitations 
We performed a very broad search of the literature using appropriate eligibility criteria by 
considering all types of study design, including preclinical studies, but we may not have 
uncovered all studies reported in abstract form. A further potential limitation of our review is the 
inclusion of animal studies, which may not be generalizable to human cases of LA poisoning. 
The consideration of animal studies to support clinical practice may be perceived as inappropriate 
by some. However, several editorials and reviews used animal data to support the concept of ILE 
as an antidote. Our decision to consider such methodology was driven by our intention to be as 
exhaustive as possible in a field where very little research is conducted, and when it is done, this 
is often in a non-optimal context. 
 
The human cases described were also heterogeneous regarding the LA involved, the severity of 
symptoms, the ILE dose, and the use of other treatments before ILE and we could not explore the 
potential impact of these discrepancies on the efficacy of the intervention. As stated in the 
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Methodology paper (9) the primary outcome of interest was survival. The included case reports 
showed 98% survival. However the validity of this finding is questionable because of likely 
reporting and publication bias . In most case reports the reversal of toxicity was thought to be 
related to ILE, however, some uncertainty remains as other treatments were often provided at the 
same time and effects could not be specifically distinguished. Furthermore, it is likely that cases 
that described negative outcome after ILE administration are underreported. 
Our inability to deliver some of the results as intended in the Methodology paper (9), was 
principally due to unreported data, insufficient data, or the nature of the data, and also included 
the units used to specify the dose. Our intention was to extract or calculate the total amount of 
ILE in g/kg, but in many articles the information was insufficient, and therefore different units 
appears in tables 1 and 3. As mentioned reported in the results section, most of the included 
studies and reports used 20 % ILE, but a limitation to this review is that in 11 human case reports 
and two animal studies, the actual concentration of the ILE used was not reported. 
A further limitation of the data was that it was not easy to obtain information if reported sequelae 
in human case reports referred to adverse effects from local anesthetics or from ILE. The details 
of sequelae that we were able to extract from data are included in table 1.  
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Conclusions 
 
The currently available published evidence concerning the effect of ILE in severe LA toxicity is 
limited to very low quality studies such as small animal experiments and human and animal case 
reports or series. It is possible that ILE may be effective in some cases of LA toxicity. However, 
there is currently no consistent evidence that ILE is more effective than vasopressors. The 
available evidence is insufficient to judge the combined effects of ILE and vasopressors and to 
determine whether one drug should precede the other in treating severe LA toxicity. 
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Appendix 1: Medline (ovid) search strategy for lipid emulsion therapy effect 
 
1. exp Fat Emulsions, Intravenous/ 
 2. lipid rescue.ti,ab,kw. 
 3. (lipid adj3 emulsi * ).mp. 
 4. (fat adj3 emulsi * ).mp. 
 5. ((lipid or fat * ) adj5 bolus).mp. 
 6. (lipid adj3 (resuscitat * or therap * or infus * )).mp. 
 7. (ILE adj5 (lipid * or emulsi * or fat * )).mp. 
 8. (IFE adj5 (lipid * or emulsi * or fat * )).mp. 
 9. (lipid adj3 sink * ).mp. 
 10. (lipid adj3 sequest * ).mp. 
 11. intravenous * lipid * .ti,ab,kw. 
 12. intralipid * .mp. 
 13. or/1-12 
 14. exp Cardiovascular Agents/ 
 15. exp Sodium Channel Blockers/ 
 16. exp Calcium Channel Blockers/ 
 17. exp Adrenergic beta-Antagonists/ 
 18. ((sodium or Na * ) adj3 channel block * ).ti,ab,kw. 
 19. ((calcium or Ca * ) adj3 channel block * ).ti,ab,kw. 
 20. (beta adj3 block * ).ti,ab,kw. 
 21. B-blocker.ti,ab,kw. 
 22. exp Central Nervous System Depressants/ 
 23. exp Psychotropic Drugs/ 
 24. exp Anti-Arrhythmia Agents/ 
 25. local an?esthetic * .mp. 
 26. exp Amitriptyline/ 
 27. amitriptyline.mp. 
 28. exp Bupropion/ 
 29. bupropion.mp. 
 30. exp Chloroquine/ 
 31. chloroquine.mp. 
 32. chlorpromazine.mp. 
 33. clomipramine.mp. 
 34. cocaine.mp. 
 35. exp Dothiepin/ 
 36. (dosulepin or dothiepin).mp. 
 37. glyphosate.mp. 
 38. haloperidol.mp. 
 39. lamotrigine.mp. 
 40. olanzapine.mp. 
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 41. propofol.mp. 
 42. quetiapine.mp. 
 43. exp Sertraline/ 
 44. sertraline.ti,ab,kw. 
 45. zopiclone.mp. 
 46. ropivacaine.mp. 
 47. levobupivacaine.mp. 
 48. lignocaine.mp. 
 49. diazepam.mp. 
 50. exp Carnitine/ 
 51. carnitine.ti,ab,kw. 
 52. exp Poisoning/ 
 53. poison * .ti,ab,kw. 
 54. exp Noxae/ae, po [Adverse Effects, Poisoning] 
 55. po.fs. 
 56. ae.fs. 
 57. to.fs. 
 58. exp Street Drugs/ 
 59. (lipophilic adj3 (drug * or toxin * )).ti,ab,kw. 
 60. overdos * .ti,ab,kw. 
 61. exp Antidotes/ 
 62. antidote * .ti,ab,kw. 
 63. (toxic * or intoxic * or pharmacotoxic * ).ti,ab,kw. 
 64. Resuscitation/ 
 65. resuscitat * .ti,ab,kw. 
 66. or/14-65 
 67. 13 and 66  
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Figure 1: Selection of articles flow diagram  
 
Search date December 15th 2014. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 animal citations* 76 human citations * 
29 RCSs 
6 case reports or case 
series 
2 RCTs # 
74 case reports or case 
series 
3 observational studies 
Citations after duplicates removed  
(n=11353) 
Citations screened  
(n=11353) 
Citations excluded  
(n=10515) 
 
Reason: 
Unrelated subjects (n=10515) 
Full text assessed for eligibility  
(n=838) 
 Full-text articles excluded (n= 725) 
 
Reasons: 
Duplicate data (n=30) 
Experimental studies (n=45) 
Non-Local Anesthetic articles 
(n=203) 
No patient data (n=35) 
Pharmacokinetic studies not in 
overdose (n= 2) 
 
Pre-treatment models (n=11) 
Review/Opinion article (no new 
data)  (n=204) 
 
Uninterpretable data (n=3) 
Unrelated/irrelevant (n=185)  
Unable to obtain full text 
/translation (n=7) 
 
 
Articles included in qualitative synthesis for Local 
Anesthetics 
(n=113) 
 
: 
Records identified through  
database searching  
(n=19447) 
Additional records identified  
through other sources  
(n=38) 
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*one citation included both one animal study and one human case report. # The two citations covers one 
single study.  
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Table 1. Summary of the 16 volunteers from a crossover randomized controlled trial, and 83 patients from 73 case 
reports and one case series included in the systematic review. 
 
ACLS: Advanced cardiac life support, AV: Atrio-ventricular, BP: Blood Pressure, CNS: Central nervous system, CPR: Cardiopulmonary resuscitation, ICU: Intensive care unit, GCS: Glasgow coma 
score, HR: Heart rate, ILE: Intravenous lipid emulsion, LA: Local anesthetic, LCT: Long-chain triglyceride, MAP: Mean arterial pressure, MCT: Medium-chain triglyceride, NR: Not reported, 
PVC: Premature ventricular contractions, RCT: Randomized controlled trial, ROSC: Return of spontaneous circulation, VT: Ventricular tachycardia.  
Note: Lidocaine and lignocaine are synonyms for the same compound, and the name lidocaine is used in the table. 
#: The total dose in g/kg was infrequently available, and could only be calculated if bodyweight was reported.  
¤: Available as abstracts only at the time of writing. 
 
Reference Study 
type 
Age/sex, 
weight 
Local 
anesthetic and 
dose 
Log D 
(129) 
Route of 
administration 
Symptoms ILE used ILE dose# ILE 
only 
used 
Other treatments 
received, dose 
included if 
reported  
ILE effect Outcome 
RCT             
Dureau 
2014/R010+R011 (10, 
11) ¤ 
RCT, 
cross-
over 
Age 18-40 
y/8F+8M 
Ropivacaine or 
Levobupivacaine; 
Continued infusion 
doses 8 mg/min, 
maximum 120 mg or 
until early signs of 
toxicity such as 
paresthesias or 
inebriation sensation 
reached.  
4.21 
2.68 
Infusion Neurologic impregnation 
(parasthesia, inebriation) 
QRS broadening at LA cessation 
20%, 
Intralipid 
120 mL bolus Yes Saline (120 ml) on two study 
days (Control group) 
Study confirms the 
Lipid Sink hypothesis in 
humans, but unable to 
demonstrate any 
clinical benefit of ILE 
4 out of 16 volunteers 
reached maximum dose. 
Mean dose to reach mild 
toxicity threshold was not 
different in ILE vs control 
groups ., (75.7 =/- 29.1 mg 
vs 81.7 =/-22.3 mg for 
ropivacaine  and 69.4 =/- 
26.2 mg vs 80.8 =/- 31.7 mg 
for levobupivacaine 
Case reports/series             
AdMani, 2010 (12) Case 
report 
3 mth/M, 5.9 
kg 
Bupivacaine 25 mg, 
Lidocaine 100 mg 
2.68 
1.26 
Subcutaneous Seizure. bradycardia with block 
then Ventricular fibrillation and 
Ventricular tachycardia 
20%, 
Intralipid 
9 mL (0.31 g/kg) 
bolus then 0.25 
mL/kg/min (0.51 
g/kg/hr) 
No Dexamethasone 2mg, 
hydrocortisone 20mg, 
thiopental 5mg 
Mechanical ventilation 
Probably no effect 
required benzodiapine 
after seizures restarted 
in ICU 
Survival, 
no sequelae 
Al-Alami, 2011 (13) Case 
report 
16 y/M,  
58 kg 
Ropivacaine 300 mg 4.21 Nerve block Confusion, visual hallucinations 
slurred speech tremor  
Sinus tachycardia and 
hypertension 
20%, 
Intralipid 
0.0015 g/kg bolus 
then 0.015 g/kg/hr 
in 3 hrs 
No Midazolam 0.5 mg ILE was safe and 
successful in reversing 
LA-induced early CNS 
and cardiac 
abnormalities 
Survival, 
no sequelae 
Aveline, 2010 (14) Case 
report 
52 y/F, 
57 kg 
Lidocaine 400 mg,  
Ropivacaine 112.5 mg 
1.26 
4.21 
Nerve block GCS 7, agitated, confused, 
jerking arms/head 
20%, 
Intralipid 
100 mL (0.35 g/kg) 
x2 bolus 
No Midazolam 3mg, thiopental 
300mg and suxamethonium 
80mg 
Intubation 
ILE not effective Survival, 
no sequelae 
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Reference Study 
type 
Age/sex, 
weight 
Local 
anesthetic and 
dose 
Log D 
(129) 
Route of 
administration 
Symptoms ILE used ILE dose# ILE 
only 
used 
Other treatments 
received, dose 
included if 
reported  
ILE effect Outcome 
Bazerbachi, 2013 (15) Case 
report 
57 y/M, 
weight NR 
Ropivacaine 1540 mg 4.21 Nerve block Lethargic, hallucinations 
Bradycardia, wide QRS, 
prolonged QT, ejection fraction 
20% 
Cardiac arrest 
Tinnitus, dysgeusia 
20%, 
Intralipid 
Total dose 2480 mL No Plasmapheresis Suggest the failure of 
ILE rescue. 
Died from cardiac arrest 
Bilotta, 2012 (16) Case 
report 
53 y/M, 
weight NR 
Lidocaine 500 mg,  
Ropivacaine 3000 mg 
1.26 
4.21 
Nerve block AV block, HR 28/min, MAP 40 
mmHg 
20%, 
Intralipid 
100 mL bolus (<5 
min) then 100 mL in 
20 min 
No Atropine 0.5 mg, 
phenylephrine 10 mg 
Rapid beneficial effect Survival, 
no sequelae 
Buckenmaier, 2012 
(17) 
Case 
report 
29 y/M, 
weight NR 
Ropivacaine,  
Mepivacaine.  
Bolus and continued 
infusion doses of both, 
total dose NR. 
4.21 
1.40 
Nerve block Unresponsive, cardiac arrest Intralipid 1 mL/kg x3 bolus No Epinephrine, atropine, 
amiodarone, calcium, 
sodium bicarbonate, 
magnesium, thrombolytic 
therapy 
CPR 
NR Died from blast injuries 
complicated by LA toxicity 
resulting in a fatal cardiac 
arrhythmia 
Calenda, 2009 (18) Case 
report 
72 y/M, 
60 kg 
Mepivacaine 300 mg, 
Ropivacaine 112.5 mg 
1.40 
4.21 
Nerve block Numb mouth/tongue 
Seizures  
Tachycardia (130/min) 
20%, 
Intralipid 
250 mL (0.83 g/kg) 
bolus 
No Midazolam 5 mg, propofol 
150 mg (1st seizure); 
Thiopental 125 mg (2nd 
seizure)  
Mechanical ventilation 
ILE not effective in 
stopping 2nd seizure 
Survival, 
no sequelae 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 1 
Age NR/M, 
weight NR 
Lidocaine 560 mg 1.26 Nerve block Hypertension 
Drowsy 
NR NR NR NR NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 2 
67 y/F, 
49 kg 
Lidocaine 200 mg, 
Bupivacaine 75 mg 
1.26 
2.68 
Nerve block Seizure 20%, 
Intralipid 
1.5 mL/kg (0.30 
g/kg) bolus then 
400 mL (4.9 g/kg/hr) 
in 20 min. Total 
dose 500 mL (2.04 
g/kg) 
No Midazolam ILE was thought to 
have prevented death 
Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 3 
NR Mepivacaine 900 mg, 
Bupivacaine 100 mg 
1.40 
2.68 
Nerve block Decreased level of 
consciousness 
NR NR NR NR NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry)(19) 
Case 
series, 
No 4 
68 y/M, 
75 kg 
Ropivacaine 200 mg 4.21 Nerve block Seizure 
Cardiac arrest 
20%, 
Intralipid 
100 mL (0.27 g/kg) 
x3 bolus. 
Total dose 300 mL 
(0.80 g/kg) 
No Midazolam, epinephrine, 
sodium bicarbonate, 
magnesium, and 
hydrocortisone 
NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 5 
69 y/F, 
80 kg 
Bupivacaine 150 mg 2.68 Nerve block Seizure 
Cardiovascular collapse 
20%, 
Intralipid 
1.5 mL/kg (0.30 
g/kg) bolus then 
400 mL/hr (1.0 
g/kg/hr). 
Total dose 500 mL 
(1.25 g/kg) 
NR NR ILE was thought to 
have prevented death 
Survival, 
sequelae NR 
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Reference Study 
type 
Age/sex, 
weight 
Local 
anesthetic and 
dose 
Log D 
(129) 
Route of 
administration 
Symptoms ILE used ILE dose# ILE 
only 
used 
Other treatments 
received, dose 
included if 
reported  
ILE effect Outcome 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 6 
NR Bupivacaine 50 mg 2.68 Nerve block Seizure NR NR NR NR NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 7 
NR Bupivacaine 100 mg 2.68 Nerve block Seizure NR NR NR NR NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 8 
30 y/M, 
81 kg 
Bupivacaine 100 mg 2.68 Nerve block Seizure 20%, 
Lipofundin 
1.5 mL/kg (0.30 
g/kg) bolus then 15 
mL/min (2.22 
g/kg/hr) 
Total dose 640 mL 
1.58 g/kg) 
NR NR ILE was thought to 
have prevented death 
Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 9 
47 y/F, 
60 kg 
Bupivacaine 187.5 mg 2.68 Subcutaneous Decreased level of 
consciousness 
20%, 
Intralipid 
1.5 mL/kg (0.30 
g/kg) bolus then 13 
mL/min (2.58 
g/kg/hr) 
Total dose 900 mL 
(3.0 g/kg) 
NR NR NR Survival, 
sequelae NR 
Cave, 2014 (Lipid 
Registry) (19) 
Case 
series, 
No 10 
75 y/F, 
57 kg 
Bupivacaine 1595 mg 2.68 Nerve block Seizure 20%, 
Intralipid 
1.5 mL/kg (0.30 
g/kg) bolus then 
870 mL/hr (3.05 
g/kg/hr) 
Total dose 587 mL 
1.95 g/kg) 
NR NR NR Survival, 
sequelae NR 
Charbonneau, 2009 
(20) 
Case 
report 
19 y/sex NR, 
67 kg 
Mepivacaine 1000 mg 1.40 Nerve block Dysarthria, myoclonia, 
confusion 
20%, 
Medialipid 
100 mL (0.30 g/kg) 
bolus  
No Midazolam 1 mg, 
clonazepam 1 mg 
Efficacy was immediate 
and complete 
Survival, 
no sequelae 
Contargyris, 2012 
(21) 
Case 
report 
26 y/F, 34w 
pregnant, 
51/58 kg 
Bupivacaine 7 mg, 
Ropivacaine 90 mg 
2.68 
4.21 
Nerve block headache, metallic taste, 
hallucinations 
20%, 
Intralipid 
200 mL (0.78 g/kg 
mother) bolus 
Yes NR Resolution of 
symptoms 
Survival, 
sequelae NR 
Cordell, 2010 (22) Case 
report 
17 y/F, 
weight NR 
Bupivacaine 75 mg 2.68 Nerve block Seizure 
Tachycardia (180/min) 
20%, 
brand NR 
100 mL x3 bolus, 
then infusion. Total 
dose NR 
No Midazolam 2 mg, propofol 
100 mg and epinephrine 1 
mg 
CPR, intubation 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
Dacosta, 2009 (23) ¤ Case 
report 
44 y/F,  
104 kg 
Lidocaine 150 mg 
Bupivacaine 200 mg 
1.26 
2.68 
Nerve block Metalic taste 
Sinus bradycardia (34/min), 
hypotension (80/45 mmHg) 
NR 100 ml in 10 min. No Atropine 2mg, ephedrine 5 
mg, saline 500 ml 
Resolution of cardiac 
symptoms in 15 min. 
Survival, 
no sequelae 
Diaz, 2012 (24) Case 
report 
Adult/F,  
75 kg 
Levobupivicaine 34.25 
mg, Lidocaine 340 mg 
2.68 
1.26 
Nerve block Somnolent, developed tremor, 
nystagmus and became 
comatose 
Decrease in blood pressure 
Nausea 
20%, 
Medialipid 
(MCT/LCT) 
100 mL (0.27 g/kg) 
bolus then 400 mL 
(0.53 g/kg/hr) in 2 
hrs 
No Phenylephrine, ondansetron 
4 mg, sufentanil 20.5 mcg, 
clonidine 138 mcg 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
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Reference Study 
type 
Age/sex, 
weight 
Local 
anesthetic and 
dose 
Log D 
(129) 
Route of 
administration 
Symptoms ILE used ILE dose# ILE 
only 
used 
Other treatments 
received, dose 
included if 
reported  
ILE effect Outcome 
Dix, 2011 (25) Case 
report 
57 y/M, 
weight NR 
Lidocaine 120 mg + 2 
mg/min infusion, total 
dose NR 
1.26 Intravenous Somnolent, confused, 
unresponsive 
QRS widening, Suffered from 
cardiovascular disease already- 
Pulseless, electromechanical 
dissociation 
Tremor, difficulty performing 
cerebellar testing 
20%, 
Intralipid 
1 mL/kg bolus then 
0.25 mL/kg/min in 
30 min 
No Epinephrine, amiodarone, 
magnesium sulfate, calcium 
gluconate, and sodium 
bicarbonate, dopamine 7 
mcg/kg/min 
CPR 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Egan 2013 (26)  ¤ Case 
report 
38 y/F, 
62 kg 
Ropivacaine 100 mg,  
Lidocaine 200 mg 
4.21 
2.26 
Nerve block Grand mal seizures 1 minutes 
post injection 
Coma 
20% 
Intralipid 
100 mL (0.32 g/kg) 
bolus then  0.25 
mg/kg/hr infusion,  
duration NR 
No Midazolam >2 mg 
Intubation 
 
Resolution of seizure 
unclear timing 
Resolution of coma 30 
minutes later 
 
Survival, 
no sequelae 
Espinet, 2009 (27) Case 
report 
36 y/M, 
80 kg 
Bupivacaine 100 mg, 
Lidocaine 100 mg 
2.68 
1.26 
Nerve block Perioral tingling, headache, 
dizziness, light headedness, 
diplopia 
Tachycardia (153/min), BP 
180/110mmHg, ST depression  
20 %, 
Intralipid 
100 mL (0.25 g/kg) 
x2 bolus then 100 
mL (0.25 g/kg/hr) in 
1 hour 
No Crystalloid (Hartmann’s 
solution) 1 L 
Oxygen 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
Etesse, 2011 (28) Case 
report 
23 y/F, 38w 
pregnant, 
weight NR 
Ropivacaine 46 mg 4.21 Nerve block Visual hallucination, nausea 
7 hour prior to development of 
status epilepticus 
Hypertension 
NR 100 mL  No Midazolam 2mg, 
magnesium sulfate 1 g in 20 
min and then 1 g/hr  
Oxygen 
Resolution of 
neurologic symptoms 
Survival, 
no sequelae 
Fenten 2014 (29) Case 
report 
67 y/F, 
weight NR 
Ropivacaine 400 mg 4.21 Intra articular/  
Subcutaneous 
Chest pain 
Coma 
Seizure 
20%, brand 
NR 
Infusion 
Unknown duration 
No Nitroglycerin (spray), 
metoprolol 5 mg,  
midazolam 1 mg boluses 
Oxygen 
Resolution of initial 
seizure but recurrence 
of seizures and 
twitching for 5.5 hr 
after 
Survival, 
no sequelae 
Foxall, 2007 (30) Case 
report 
75 y/F, 
85 kg 
Levobupivacaine 100 
mg 
2.68 Nerve block Unresponsiveness 
Seizures 
QRS widening; Suffered from 
cardiovascular disease already 
Groaned 
20%, 
Intralipid 
100 mL (0.24 g/kg) 
bolus in 5 min 
No Metaraminol 0.5 mg, 
propofol 80 mg, 
suxamethonium 100 mg 
Oxygen, intubation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
French, 2012 (31) ¤ Case 
report 
11 mth/M, 
9.9 kg 
Lidocaine 100 mg 1.26 Intraosseous Status epilepticus 20%, 
Intralipid 
12 mL (0.24 g/kg) 
bolus 
No Lorazepam 0.1 mg/kg NR Survival, 
no sequelae 
Fuzaylov, 2010 (32) Case 
report 
13 y/F, 
50 kg 
Bupivacaine 25 mg 2.68 Intravenous Decreased BP (from 90 to 
60mmHg) and broad complex 
ventricular tachycardia 
20%, 
Intralipid 
100 mL (0.4 g/kg)  
bolus 
No Saline 500 mL. Epinephrine 
10 mcg x2 bolus + 0.1 
mcg/kg/min infusion,  
dopamine 10 mcg/kg/min 
infusion  
CPR 
Possible effect in 
resolution of symptoms 
Survival,  
pulmonary edema, resolved 
day 4 
5 
AACT manuscript LA to edit for CTX 
 
 
Reference Study 
type 
Age/sex, 
weight 
Local 
anesthetic and 
dose 
Log D 
(129) 
Route of 
administration 
Symptoms ILE used ILE dose# ILE 
only 
used 
Other treatments 
received, dose 
included if 
reported  
ILE effect Outcome 
Gallagher, 2010 (33) Case 
report 
28 y/M 
55.8 kg 
Lidocaine 2%,  
Bupivacaine 0.5%, 50 
mL mixture LA ratio NR 
1.26 
2.68 
Subcutaneous Dizziness then coma  
Apnea 
Generalized seizure activity 
with severe tonic-clonic activity 
Sudden cardiac arrest 
20%, 
brand NR 
2 units (mL not 
reportd) 
No Sodium bicarbonate 200 
mEq, saline bolus 
Epinephrine 4 mg, 
vasopressin 40 U, atropine 4 
mg, midazolam 1 mg, 
lorazepam 2 mg 
CPR 
Resolution of cardiac 
symptoms 
Survival,  
no sequelae 
Gnaho, 2009 (34) Case 
report 
82 y/F, 
45 kg 
 
Ropivacaine 100 mg 4.21 Nerve block Lost consciousness 
Generalized tonic-clonic seizure 
Ventricular fibrillation, no pulse 
Difficulties in speaking 
20%, 
Intralipid 
70 mL (0.31 g/kg) 
bolus 
No Thiopental 325 mg, 
suxamethonium 100 mg, 
propofol 30 mg, 
epinephrine 0.3 mg 
Oxygen, intubation, CPR  
Rapid beneficial effect 
on cardiac resuscitation 
Survival, 
no sequelae 
Goyal, 2011 (35) Case 
report 
26 y/M, 
75 kg 
Bupivacaine 25 mg 2.68 Nerve block Tachycardia (244–250/min) 
and BP 50–56/30–36 mmHg 
10%, 
Intralipid 
150 mL (0.20 g/kg) 
in 15 min 
Yes NA Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Grenc, 2011 (36)  ¤ Case 
report 
84 y/F, 
weight NR 
Lidocaine 20 mg,  
Triamcinolone 80 mg 
1.26 
0.92 
Nerve block Generalized tonic-clonic 
seizures 
Cardiac arrest 
20%, 
Intralipid 
100 mL x2 bolus No Epinephrine 2 mg, atropine 
3 mg 
Intubation, CPR 
Resolution of cardiac 
symptoms; bolus ILE  
repeated due to 
persistent hypotension 
Survival, 
no sequelae 
Hartley, 2012 (37) Case 
report 
46 y/F, 
46 kg 
Bupivacaine 37.5 mg + 
18.75 mg/hr, total dose 
NR 
2.68 Nerve block Coma 
Seizures 
20%, 
Intralipid 
NR Yes Intubation Unclear if effect is 
related to ILE.   
Survival, 
sequelae NR 
Harvey, 2011 (38) Case 
report 
69 y/F, 
80 kg 
Lidocaine 50 mg, 
Bupivacaine 150 mg 
1.26 Nerve block Unresponsiveness, GCS 3 
Seizure 
HR 50/min, AV block, BP 
51/29mmHg 
20%, 
Intralipid 
100 mL (0.25 g/kg) 
bolus then 400 mL 
1.33 g/kg/hr) in 45 
min 
No Midazolam 5 mg, atropine,  
600 mcg, epinephrine 100 
mcg, metaraminol 4 mg 
Intubation, mechanical 
ventilation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Heavner, 2012 (39)  ¤ Case 
report 
60 y/F, 
weight NR 
Lidocaine 1500 mg 1.26 Intrapleural Seizure 
Cardiac arrest 
20%, 
brand NR 
500 mL bolus then 
50 mL/hr 
No Unspecified conventional 
therapy 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Hurley 2009 (40) ¤ Case 
report 
54 y/M, 
weight NR 
Bupivacaine, dose NR 2.68 NR Cardiac arrest 
Asystoly 
NR NR NR NR Resolution of toxicity 
within a few minutes 
Survival , 
no sequelae 
Jensen, 2011 (41) ¤ Case 
report 
41 y/M, 
weight NR 
Ropivacaine 600 mg 4.21 Nerve block Loss of consciousness 
Seizure 
20 %, 
Intralipid 
100 mL bolus No Diazepam 2.5 mg Resolution of 
neurologic symptoms 
Survival,  
no sequelae 
Landy, 2012 (p.463) 
(42) 
Case 
report 
59 y/sex NR, 
weight NR 
Ropivacaine 2250 mg 4.21 Nerve block Seizures 20 %, 
Intralipid 
200 mL bolus Yes NR Resolution of 
neurologic symptoms 
Survival, 
no sequelae 
Landy, 2012 
(p.701)(43) 
Case 
report 
74 y/F, 
60 kg 
Lidocaine 380 mg 1.26 Nerve block Tonic-clonic movements 20%, 
Intralipid 
200 mL (3 mL/kg 
(0.60 g/kg)) bolus  
No Flecainide Resolution of 
symptoms 
Survival, 
no sequelae 
Lange, 2012 (44) Case 
report 
31 y/M, 
61 kg 
Lidocaine 1600 mg 1.26 Subcutaneous/ 
Intraperitoneal 
Visual hallucinations, 
dysarthria, lower level of 
consciousness and became 
non-verbal 
20%, 
Intralipid 
100 mL (0.33 g/kg) 
in 10 min 
Yes NR Resolution of 
neurologic symptoms 
Survival, 
no sequelae 
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Larson, 2013 (45) Case 
report 
4 month/F, 
6.54 kg 
Lidocaine 1500 mg,  
Prilocaine 1500 mg 
1.26 
1.33 
Topical Single seizure 
Tachycardia (147/min) 
Methemoglobin level was 
22.8% 
20%, 
brand NR 
1 g/kg bolus  No Lorazepam 0.2 mg/kg i.m. 
and 0.2 mg/kg i.o., 
fosphenytoin 20 mg PE/kg. 
Methylene blue 10 mg (1.5 
mg/kg) 
Topical decontamination 
Intubation, mechanical 
ventilation 
Unclear if effect is 
related to ILE 
Survival, 
no sequelae 
Levine, 2014(46)  Case 
report 
20 y/F, 
weight NR 
Bupivacaine, dose NR  2.68 Nerve block Seizure 20 %, 
brand NR 
20 mL/kg bolus then 
0.25 mL/kg/min for 
3 hours 
Yes NR NR Survival, 
increased lipase 185 IU/L 
suggesting pancreatitis, 
resolved after 14 days 
Li  2013 (47) ¤ Case 
report 
57 y/F, 
weight NR 
Ropivacaine 75 mg,  
Lidocaine 400 mg 
4.21 
1.26 
Nerve block Severe pain, somnolent, 
pinpoint pupils 
Intralipid, 
conc. NR 
75 mL bolus then 
infusion, dose and 
duration NR 
No Naloxone 80 mcg, 
midazolam 1 mg,  propofol 
30 mg 
Resolution of 
symptoms, but 
confused and agitated 
Survival , 
no sequelae 
Lin, 2010 (48) Case 
report 
2 days/M, 
3.2 kg 
Bupivacaine 8 mg 2.68 Nerve block ST-segment elevation, QRS 
widening 
Bradycardia 
20%, 
Intralipid 
1 mL/kg (0.2 g/kg) 
bolus 
Yes No pharmaceuticals 
Intubation, CPR 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Litz, 2006 (49) Case 
report 
84 y/F, 
50 kg 
Ropivacaine 400 mg 4.21 Nerve block Dizziness, drowsiness 
Seizures 
Asystole 
20%, 
Intralipid 
100 mL (2 mL/kg 
(0.40 g/kg)) bolus, 
then 10 mL/min (2.4 
g/kg/hr)  
Total dose 200 mL 
(0.8 g/kg) 
No Thiopental 150 mg, 
epinephrine 3x 1 mg 
Intubation, CPR 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Litz, 2008 (50) Case 
report 
91 y/M, 
57 kg 
Mepivacaine 300 mg, 
Prilocaine 100 mg 
1.40 
1.33 
Nerve block Dizziness, agitation and 
developed unresponsiveness 
Bigemeny and PVCs 
20%, 
Intralipid 
100 mL (0.35 g/kg) 
bolus then 0.25 
mL/kg/min (3 
g/kg/hr)  
Total dose 200 mL 
(0.70 g/kg) 
No Dolastrone 12.5 mg Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
Liu, 2012 (51) ¤ Case 
report 
NR Bupivacaine 200 mg 2.68 Intravenous Unclear symptoms Intralipid, 
conc. NR 
110 mL (1.5 mL/kg) 
bolus then ‘low 
dose’ infusion in 2 
hrs  
Yes NR Unclear if any 
symptoms developed 
or were reversed 
Survival,  
sequelae NR 
Ludot, 2008 (52) Case 
report 
13 y/F, 
55 kg 
Lidocaine 200 mg,  
Ropivacaine 150 mg 
1.26 
4.42 
Nerve block Ventricular tachycardia with 
wide QRS 
20%, 
Medialipid 
150 mL (3 mL/kg 
(0.60 g/kg)) bolus  
Yes No pharmaceuticals 
Manual ventilation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Markowitz, 2009 (53) Case 
report 
17 y/M, 
61 kg 
Bupivacaine 100 mg 2.68 Nerve block Coma 
Status epilepticus 
Ventricular fibrillation 
20%, 
Intralipid 
500 mL (8 ml/kg 
(1.6 g/kg)), dose 
regimen NR 
No Midazolam 3 mg  
Intubation 
Unclear if effect is 
related to ILE   
Survival, 
no sequelae 
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Marraffa, 2013 (54) ¤ Case 
report 
66 y/F, 
weight NR 
Bupivacaine 420 mg 2.68 Subcutaneous CNS depression, declining 
mental status 
Generalize tonic-clonic seizure 
activity 
Systolic hypotension to 60 
mmHg 
20%, 
brand NR 
500 mL x2 bolus No Hydromorphone 60 mg with 
the LA. Bicarbonate 
empirically given, 
dopamine. Naloxone 0.4mg 
x2, icepacks were applied 
every 2 hr at the injection 
site, lorazepam 0.2 mg 
Intubation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Marwick, 2009 (55) Case 
report 
33 y/M, 
72 kg 
Bupivacaine 112.5 mg 2.68 Nerve block Seizure 
Wide QRS 
Cardiac arrest 
Dry mouth, apnea 
20%, 
Intralipid 
150 mL (0.43 g/kg) 
bolus then 350 mL 
(1.94 g/kg/hr) in 30 
min 
No Epinephrine 1 mg + 0.06 
mcg/kg/min infusion, total 
time NR. Thiopental 250 mg, 
sodium bicarbonate, insulin, 
potassium, amiodarone 300 
mg in 30 min 
Oxygen, intubation, CPR 
Resolution of cardiac 
symptoms 
Survival,  
amylase 608 IU/L 
Mazoit, 2013 (56) Case 
report 
44 y/M, 
weight NR 
Ropivacaine 260 mg 4.21 Nerve block Metallic taste, myoclonic 
movement 
Seizure 
Cardiac arrest with asystole 
20%, 
Intralipid 
100 mL bolus No Epinephrine 100 mcg 
Manual ventilation, CPR 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
McCutchen, 2008 
(57) 
Case 
report 
82 y/F, 
weight NR 
Bupivacaine 150 mg 2.68 Nerve block Seizures x2 
VT at 200/min 
20%, 
Intralipid 
100 mL bolus then 
400 mL over 15 min 
No Midazolam 3 mg, 
amiodarone 150 mg, 
unspecified ACLS drugs 
Oxygen, defibrillation 
Unclear if effect is 
related to ILE   
Survival, 
no sequelae 
Mizutani, 2011 (58) Case 
report 
24 y/M, 
66 kg 
Ropivacaine 200 mg 4.21 Nerve block Disappearance of motor 
response to stimulation 
20%, 
brand NR 
100 mL (0.30 g/kg) 
bolus  
No Propofol (titrated), fentanyl 
100 µg  
Mechanical ventilation 
during general anesthesia 
Resolution of 
neurologic symptoms, 
but unclear if effect is 
related to ILE.   
Survival, 
no sequelae 
Nguyen, 2012 (59) Case 
report 
19 y/M, 
72 kg 
Ropivacaine 75 mg 4.21 Nerve block Visual hallucinations 
Sinus tachycardia and 
hypertension 
Myoclonic movements of the 
head and neck 
20%, 
Intralipid 
100 mL (0.28 g/kg) 
bolus  
No Midazolam 2 mg x2 
Oxygen 
Resolution of 
neurologic symptoms 
Survival, 
no sequelae 
Ogugua, 2009(60)  ¤ Case 
report 
47 y/F, 
weight NR 
Bupivacaine 165 mg 2.68 Nerve block Seizure 
Asystole 
20%, 
brand NR 
160 mL bolus then 
200 mL infusion, 
duration  NR 
No Midazolam 2 mg, 
epinephrine 9 mg, ACLS 
protocol to ROSC 
Intubation 
Apparent improvement 
in cardiac output    
Survival, 
no sequelae 
Reddy, 2010 (61)  ¤ Case 
report 
59 y/M, 
weight NR 
Mepivacaine, 
Ropivacaine 
50 mL 50/50 mixture, 
conc. NR 
1.40 
4.21 
Nerve block Agitation 
Seizures 
Tachycardia (160-170 /min) 
Slurred speech 
20%, 
Intralipid 
1.5 mL/kg bolus 
then 0.25 
mL/kg/min in 60 
min 
Yes No pharmaceuticals 
Oxygen 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
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Rosenblatt, 2006 (1) Case 
report 
58 y/M, 
82 kg 
Bupivacaine 100 mg, 
Mepivacaine 300 mg 
2.68 
1.40 
Nerve block Incoherent 
Repeated seizures 
Apneic 
Asystole 
20%, 
Intralipid 
100 mL (0.24 g/kg) 
bolus then 0.5 
mL/kg/min (6.0 
g/kg/hr) in 60 min  
No Epinephrine 3 mg, atropine 
2 mg, arginine vasopressin 
40 U, amiodarone 300 mg, 
propofol 150 mg  
Mechanical ventilation, CPR, 
defibrillation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Sakai, 2010 (62) Case 
report 
40 y/F, 
40 kg 
Ropivacaine 150 mg 4.21 Nerve block Lowered responsiveness, 
paleness, peripheral coldness, 
restlessness, hypotension, 
shallow irregular breathing, 
clonic convulsions in the limbs 
20%, 
Intralipos 
5x 10 ml (0.25 g/kg) 
bolus, then 100 ml 
(0.5 g/kg) in 50 
min., then 20 ml/hr 
(0.1 g/kg/hr). Total 
dose 230 ml 
No Etilefrine (dose NR), 
diazepam 5 mg 
Resolution of 
symptoms 
Survival, 
no sequelae 
Schaeffer, 2010 (63) Case 
report 
74 y/F, 
60 kg 
Lidocaine 400 mg 1.26 Nerve block Confused, disoriented, had loss 
of consciousness and 
myoclonus of the face 
20%, 
Intralipid 
200 mL (0.67 g/kg) 
bolus 
Yes NR Apparent improvement 
of symptoms, but 
unclear if effect is 
related to ILE 
Survival, 
no sequelae 
Schellhammer 2011 
(64) 
Case 
report 
54 y/F, 
weight NR 
Mepivacaine 1000 mg 1.40 Nerve block Dysphagia, dyspnea, PVC with 
bigeminy, ventricular 
tachycardia 145 bpm, perioral 
automatisms, dysarthria, 
hallucinations, progressive loss 
of consciousness and finally 
seizure 
20%, 
Lipofundin 
Infusion, specific 
dose and duration 
NR 
No Amiodarone 5 mg/kg, 
midazolam, propofol 
Oxygen 
Transient improvement 
in level of 
consciousness 
Survival , 
no sequelae 
Scherrer 2013 (65) ¤ Case 
report 
25 y/F, 
weight NR 
Ropivacine 450 mg  
 
4.21 Intraperitoneal/ nerve 
block 
Seizure, ventricular arrhythmia 20%, 
brand NR 
Infusion, specific 
dose and duration 
NR 
Yes NR Ventricular arrhythmia 
converted to sinus 
rhythm 
Survival, 
sequelae NR 
Schwarzkopf, 2011 
(66) ¤ 
Case 
report 
NR Prilocaine 300 mg,  
Bupivacaine 50 mg 
1.33 
2.68 
Nerve block Seizures 
Hypertension 
20%, 
brand NR 
1.5 mL/kg bolus 
then 0.1 mL/kg in 
30 min 
No Midazolam 10 mg 
Manual ventilation 
Unclear if effect is 
related to ILE 
Survival, 
sequelae NR 
Shah, 2009 (67) Case 
report 
40 days/M, 
4.96 kg 
Bupivacaine 10 mg 2.68 Nerve block BP 31/19 mmHg; tachycardia 
(170/min); The ST segment was 
noted to be elevated 2–3 mm 
and the T-wave was inverted 
20%, 
Intralipid 
10 mL (2 mL/kg (0.4 
g/kg)) bolus  
No Epinephrine 2 mcg/kg x2, 
albumin 5% 20 mL. 
Mechanical ventilation 
during general anesthesia 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Shenoy, 2014 (68) Case 
report 
3 y/sex NR, 
11 kg 
Bupivacaine 25 mg 2.68 Nerve block Pulseless ventricular 
tachycardia 
20%, 
brand NR 
15 mL (0.27 g/kg) 
bolus then 150 
mL/hr (2.73 
g/kg/hr) in 15 min, 
then 5 mL (0.091 
g/kg) bolus. Total 
dose 170 mL (3.1 
g/kg) 
No Epinephrine 0.03 mg  
Oxygen, CPR 
Beneficial effect with 
resolution of cardiac 
symptoms together 
with other treatments. 
Survival, 
no sequelae 
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Shih, 2011 (69) Case 
report 
69 y/F, 
48.5 kg 
Lidocaine 225 mg,  
Bupivacaine 37.5 mg 
1.26 
2.68 
Nerve block Bradycardia, reduced blood 
pressure 
Obtuned, unable to fully 
arouse 
20%, 
Lipovenoes 
50 mL (0.21 g/kg) 
bolus 
No Atropine 0.5 mg x3, 
ephedrine 10 mg 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
Smith, 2008 (70) Case 
report 
83 y/M, 
75 kg 
Bupivacaine 130 mg 2.68 Nerve block Loss of consciousness 
Seizure 
Pulseless wide complex 
tachycardia and asystole 
20%, 
brand NR 
250 mL (3 mL/kg 
(0.60 g/kg)) bolus 
then 0.2 mL/kg/min 
(2.4 g/kg/hr) 
No Epinephrine 1 mg, atropine 
1 mg (dosed after lipid 
emulsion), midazolam 2 mg. 
Oxygen, manual ventilation, 
CPR; then intubation, 
mechanical ventilation 
Resolution of cardiac 
symptoms , but unclear 
of effect is related to 
ILE 
Survival,  
no sequelae 
 
Sonsino, 2009 (71) Case 
report 
92 y/F, 
weight NR 
Ropivacaine 150 mg 4.21 Nerve block Generalized tonic-clonic seizure 
x1 
Asystole 
Kabiven 
2000,  
conc. NR 
50 mL bolus No Propofol 30 mg, 
epinephrine  0.3 mg (ACLS). 
Intubation, mechanical 
ventilation  
Resolution of cardiac 
symptoms 
Survival,  
no sequelae (died from 
bronchopneumonia 10 days 
after) 
Sorrenti 2014 (72) ¤ Case 
report 
46 y/M, 
weight NR 
Mepivacaine 360 mg 1.40 Nerve block Dysarthria, confusion, loss of 
verbal contact, agitation, 
tachycardia, hypertension 
20% 
Intralipid 
150 mL bolus then 
0.25 mL/kg/min. 
Total dose 250 mL 
No Midazolam 2.5 mg Resolution of 
neurological and 
cardiac symptoms 
Survival , 
no sequelae 
Spence, 2007 (73) Case 
report 
18 y/F, 38w 
pregnant, 
86 kg 
Lidocaine 80 mg,  
Bupivacaine 65 mg 
1.26 
2.68 
Nerve block Restless, agitated, did not obey 
commands, unresponsive. Fetal 
heart rate decelerating 
20%, 
Intralipid 
50 mL (0.12 g/kg) x2 
bolus  
No General anesthesia for 
delivery  
Neonatal intubation 
Resolution of 
neurologic symptoms 
Survival, 
no sequelae 
Sturini, 2010 (74) ¤ Case 
report 
NR Mepivacaine 750 mg 1.40 Intravenous Numbness, light headedness 
dizziness slurred speech 
20%, 
Intralipid 
100 mL bolus Yes NR Possibly prevented 
cardiac symptoms from 
LA toxicity 
Survival, 
no sequelae 
Süzer 2011 (75) Case 
report 
71 y/M, 
78 kg 
Bupivacaine 50 mg, 
Lidocaine 200 mg 
2.68 
1.26 
Nerve block Loss of consciousness, 
dyspnea, hypotension 65/40 
mmHg, ventricular 
extrasystoles, tachycardia 140 
bpm, seizures 
20% 
Intralipid 
0.5 mL/kg/min (6.0 
g/kg/hr) infusion. 
Total dose 500 mL 
(1.3 g/kg) 
No Midazolam 5 mg, 
epinephrine 10 mg, 
amiodarone 150 mg 
Intubation 
Resolution of cardiac 
symptoms within 3 
min, resolution of 
neurological  symptoms 
within total dose 
administered 
Survival , 
no sequelae 
Ter Horst, 2010 (76) Case 
report 
27 y/F, 
weight NR 
Ropivacaine 300 mg 4.21 Nerve block Decreased level of 
consciousness 
Seizure 
20%, 
Intralipid 
100 mL (1.5 mL/kg) 
bolus then 400 mL 
in 1.5 hrs 
No Midazolam 5 mg x2. 
Mechanical ventilation until 
resolution of respiratory 
symptoms 
Rapid beneficial effect 
on neurologic 
symptoms 
Survival, 
no sequelae 
Varela, 2010 (77) Case 
report 
83 y/F, 
70 kg 
Bupivacaine 150 mg, 
Ropivacaine 300 mg 
2.68 
4.21 
Nerve block Repeated seizures. 
Bradycardia, hypotension, first 
degree heart block, multifocal 
PVC, VT 
20%, 
Liposyn 
250 mL (1.43 
g/kg/hr) x2 infusion, 
each in 30 min  
No Atropine 1 mg, midazolam 4 
mg. ACLS protocol). 
Intubation, oxygen, manual 
ventilation 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Warren, 2008 (78) Case 
report 
60 y/M, 
83 kg 
Mepivacaine 450 mg,  
Bupivacaine 50 mg 
1.40 
2.68 
Nerve block Unresponsiveness. 
Cardiac arrest. 
Labored respiration 
20%, 
Liposyn III 
250 mL (1.2 g/kg/hr) 
infusion in 30 min 
No Sodium bicarbonate 8.4% 
100 mL, atropine 1 mg, 
epinephrine 1 mg x3, 
vasopressin 40U, 
magnesium sulfate 6 g  
CPR, defibrillation x11 
Longer intervals of 
sustained cardiac 
rythm during 
defibrillation 
Survival, 
no sequelae 
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Whiteman 2014 (79) Case 
report 
32 y/F, 
62 kg 
Bupivacaine 870 mg 2.68 Nerve block Confusion, agitation, 
combative then seizures, 
cardiac arrhythmia 
20% 
Intralipid 
1.5 mL/kg (0.3 g/kg) 
bolus then 0.25 
mL/kg/min (3.0 
g/kg/hr) for 60 min 
No Unspecified medical 
therapy, cardiac 
defibrillation x2, surgery 
with evacuation of 60 mL 
fluid from the right rectus 
sheath  
CPR 
ROSC and normocardia 
after 45 min. 
Resolution of cardiac 
arrythmia the following 
day 
Survival , 
no sequelae 
Whiteside, 2008 (80) Case 
report 
Elderly/F, 
74 kg 
Levobupivacaine 21.65 
mg 
2.68 Nerve block Seizure. 20%, 
Intralipid 
100 mL (1.5 mL/kg 
(0.30 g/kg)) bolus 
Yes No pharmaceuticals 
Oxygen, manual ventilation 
Unclear of effect is 
related to ILE 
Survival, 
no sequelae 
Widfeldt 2014 (81) Case 
report 
62 y/F, 
weight NR 
Ropivacaine 150 mg 4.21 Nerve block Unconsciousness, nystagmus, 
muscle twitching 
20%, 
Intralipid 
100 mL (1.5 mL/kg) 
x2 bolus – 10 min 
interval, then 50 
mL/hr for 10 hrs 
No Diazepam, few doses 
(specific dose NR) 
Resolution of 
neurologic symptoms 
Survival , 
no sequelae 
Wong, 2010 (82) Case 
report 
6 y/M, 
24 kg 
Bupivacaine, dose NR  2.68 Nerve block Sinus bradycardia (60/min)  
that rapidly proceeded to a 
wide complex ventricular 
arrhythmia at 40/min and 
hypotension to BP 65 ⁄ 35 
mmHg and tachycardia 
120/min 
20%, 
Intralipid 
20 mL (0.17 g/kg) 
bolus 
No Crystalloid fluid boluses 20 
mL/kg, atropine 0.4 mg, 
epinephrine 0.2 mg then 
continued 0.1 mg boluses to 
maintain a systolic pressure 
> 60 mmHg then 0.2 
µg/kg/min infusion. 
Packed red cells (300 mL) + 
5% albumin (250 mL)  
CPR 
Resolution of cardiac 
symptoms 
Survival,  
no sequelae for 3 days. 
After 8 days, brain stem 
death from cerebral 
ischemia not related to ILE 
treatment 
Zhurda, 2010 (83) Case 
report 
78 y/M, 
62 kg 
Bupivacaine 100 mg 2.68 Nerve block Perioral numbness, muscle 
twitching, agitation, difficult 
accommodation 
HR 38/min which became wide 
complex and hypotension to 
75/35mmHg 
20%, 
Intralipid 
60 mL (0.19 g/kg) 
bolus 
No Midazolam 3 mg, atropine 
Oxygen 
Resolution of cardiac 
symptoms 
Survival, 
no sequelae 
Zimmer, 2007 (84) Case 
report 
84 y/F, 
53 kg 
Bupivacaine 43 mg 2.68 Nerve block Agitation, confusion, restless. 
Seizure. 
Supraventicular tachycardia 
(150/min) ventricular extra 
systole, hypertension (170/85 
mmHg) 
Heat sense in feet 
20%, 
Lipofundin 
100 mL (0.38 g/kg) 
bolus then 0.5 
mL/kg/hr (0.1 
g/kg/hr) 
No Clonidin 150 mcg, 
midazolam 5 mg, lidocain 
100 mg, propofol 1% 50 mg 
x2 
Resolution of cardiac 
and neurologic 
symptoms 
Survival, 
no sequelae 
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Table 2: Reported local anesthetics in the 16 volunteers from the randomized 
controlled study and the 83 patients from case reports and case series included 
in the systematic review.  
Local anesthetic 
Reported 
cases, n Combination local anesthetics 
Reported 
cases, n 
Lidocaine** 8 Mepivacaine/Prilocaine  1 
Bupivacaine 26 Mepivacaine/Ropivacaine 3 
Mepivacaine 4 Lidocaine**/Ropivacaine  5 
Ropivacaine 33* Lidocaine**/Levobupivacaine 1 
Levobupivacaine 18* Lidocaine**/Prilocaine  1 
  Bupivacaine/Lidocaine**  9 
  Bupivacaine/Mepivacaine 3 
  Bupivacaine/Ropivacaine 2 
  Bupivacaine/Prilocaine 1 
*The 16 volunteers received ropivacaine and levobupivacaine on each occasion, both are 
included in the table.  
**Note: Lidocaine and lignocaine are synonyms : lidocaine is used in the table.  
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  Table 3. Summary of the 38 animal studies included in the systematic review on the effect of ILE 
 
* Drugs used for general anesthesia or euthanasia are not included. 
ACLS: Advanced cardiac life support, AH: Atrial-His interval, ATP:Adenosine triphosphate, AUC: Area under the curve, BP: Blood pressure, CI: Cardiac index, CVP: Central venous pressure, 
CVT: CVT-4325, ECG: electrocardiogram, EPI: Epinephrine, HR: Heart rate, HV: His-ventricle interval, ILE: Intravenous lipid emulsion, IO: Intraosseous, IV: Intravenous, LA: Local anesthetic, 
LCT: Long chain triglyceride, LVdP/dtmax: maximal first derivative of left ventricular pressure, LVEDP: Left ventricular end-diastolic pressure, MAoP: Mean aortic pressure, MAP: Mean 
arterial pressure, MCT: Medium chain triglyceride, mPAP: Mean pulmonary artery pressure, NA: Not applicable, NR: Not reported, PCP: Pulmonary capillary pressure, pHm: Myocardial pH, 
PmO2: Myocardial tissue oxygen pressure, PVRI: Pulmonary vascular resistance index, RCS: Randomized controlled studies, ROSC: Return of spontaneous circulation, RPP: Rate pressure 
product, RR: Cardiac cycle length, std CPR: Standard cardio-pulmonary resuscitation, std resusc: Standard resuscitation, SVRI: Systemic vascular resistance index, VASO: Vasopressin. 
#: The bolus dose in g/kg and infusion dose in g/kg/hronly be calculated if lipid concentration was reported.  
¤: Available as abstracts at the time of writing. 
Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
RCS              
Bonfim, 2012 (85) 
(Pig) 
RCS;  
compared LCT 
and MCT/LCT 
Ropivacaine 
(7 mg/kg in 30 
sec) 
4.21 Decrease in 
mean arterial 
pressure 
20%, 
Lipovenos 
MCT and 
Lipovenos 
4 mL/kg 
(0.8 g/kg) 
No MCT/LCT ILE  
vs 
LCT ILE   
vs 
Saline 
 
Other 
treatment and 
study treatment 
at 1 min. 
Vasopressors: 
0.8 g/kg 
At 30 min increase MAP 
(LCT = MCT/LCT), CI (only 
MCT/LCT), SVRI (LCT = 
MCT/LCT), PVRI (only 
MCT/LCT); no effect HR, 
CVP, mPAP, PCP 
Survival: All 
 
Yes; For both LCT and 
MCT/LCT 
Buckenmaier, 2012 
(17) 
(Pig) 
RCS;  
post mortem 
distribution study 
Ropivacaine 
(1.5 mg/kg/min) 
4.21 Asystole 20%, 
Intralipid 
1 mL/kg 
(0.2 g/kg) 
No ILE  
vs  
No ILE 
 
LA and study 
treatment were 
dosed 
simultaneously 
Saline 1-2 
mL/kg/hr 
Asystole;  
Earlier onset of death 
(asystole) in ILE compared 
to non-ILE 
Survival: ILE 0/6,  
No ILE 0/6 
 
No; Post-mortem study 
Bushey, 2011 (86) 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine 
(5 mg/kg) 
2.68 Cardiovascular 
collapse 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
for 10 min 
ILE  
vs  
Saline 
Other 
treatments at 4 
min., then 
study treatment 
ACLS 
resuscitation 
and closed 
chest 
compression 
ROSC (unsupported systolic 
BP of 60 mmHg or greater 
for 10 min) 
Survival: ILE 6/12,  
Saline 4/12 
No; suggest that the 
addition of ILE to ACLS 
intervention does not 
improve survival 
Candela, 2010 (87) 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine 
(4 mg/kg) 
2.68 Lengthening of 
HV, QRS, AH and 
PQ intervals, no 
alteration in RR 
and JTc intervals. 
Haemodynamics: 
decrease in 
LVdP/dtmax, 
increase in 
LVEDP, no 
change in MAoP 
20%, 
Medialip 
and Ivelip 
1.5 mL/kg 
(0.3 g/kg) 
0.25 
mL/kg/min 
(3  g/kg/hr) 
(MCT/LCT and LCT) 
ILE+Saline  
vs  
Saline 
 
Study 
treatment at 30 
sec. 
No Hemodynamics : LCT and 
MCT/LCT – MAoP and 
LVdP/dTmax were 
increased by ILE  therapy 
when comparing AUC; 
QRS width: LCT and 
MCT/LCT – Effects on QRS 
duration was reversed 
Survival: LCT 7/7,  
MCT/LCT 8/8,  
Saline 9/9 
Yes 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
De Queiroz, 2012 
(88) ¤ 
(Pig) 
RCS;  
resuscitation 
model 
Levobupivacaine 
(500 mg/hr until 
symptoms) 
2.68 MAP decrease by 
50% for 15 sec 
20%, 
brand NR 
4 mL/kg 
(0.8 g/kg) 
0.25 
mL/kg/min 
(3 g/kg/hr) 
ILE  
vs  
ILE+EPI 
vs  
EPI  
vs 
Control (no 
additional drugs) 
NR EPI 10mg/kg 
every 3min 
Hemodynamics:  
Cardiovascular collapse 
defined by a decrease in 
MAP by 50%;  
EPI alone or in combination 
with ILE was associated 
with rhythmic or 
conduction cardiac 
disturbances 
Survival: ILE 7/9,  
ILE+EPI 10/10,  
EPI 6/7,  
Control 1/7, 
Yes 
De Queiroz, 2014 
(89) 
(Pig) 
RCS; 
resuscitation 
model 
Levobupivacaine 
(8.3 mg/min) 
2.68 MAP decreased 
to 50% of its 
baseline value 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.25 
mL/kg/min 
(3 g/kg/hr) 
ILE 
 vs  
EPI  
vs  
ILE+EPI  
vs  
Saline 
Std CPR 
immediately, 
then study 
treatment 
Std CPR (chest 
compressions 
and manual 
ventilation) 
Time to ROSC in survivors:  
ILE 460 sec, EPI 296 sec, 
ILE+EPI 304 sec, Saline 720 
sec 
ECG abnormalities 
(arrhythmia; conduction) 
number, after ROSC in 
survivors: 
ILE (0;0), EPI (11;3), ILE+EPI 
(10;7)  
Survival: ILE 7/9,  
EPI 6/7,  
ILE+EPI 10/10,  
Saline 1/7 
Yes; ILE, EPI, and 
ILE+EPI provided 
similar ROSC. ECG 
abnormalities from EPI 
or ILE+EPI increased 
compared to ILE 
de Simone, 2012 
(90) ¤ 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine 
(5 mg/kg) 
2.68 Fall in arterial BP, 
cardiac index, 
ventricular 
systolic work 
index mainly and 
no important 
changes in 
vascular 
resistances 
20%, 
SMOFLipid 
4 mL/kg 
(0.8 g/kg) 
No ILE  
vs  
Saline 
Study 
treatment at 1 
min. 
No Hemodynamics: ILE 
improved BP by increasing 
vascular resistance 
compared to saline; 
QRS width: No 
improvement in "cardiac 
index" 
Survival: NR Yes; ILE is an option for 
reversing hypotension 
in cases of intoxication 
by bupivacaine   
Di Gregorio, 2008 
(91) ¤ 
(Rats) 
RCS; 
resuscitation 
model 
Bupivacaine 
(20 mg/kg) 
2.68 Cardiac arrest 30%, 
Soy bean 
oil 
emulsion 
5 mL/kg 
(1.5 g/kg) 
0.5 
mL/kg/min 
(9 g/kg/hr) 
ILE  
vs  
EPI 
vs  
Saline  
 
NR cardiac 
resuscitation 
QRS width: Bupivacaine-
induced QRS prolongation 
reverted to normal in both 
ILE and EPI groups but 
persisted in Saline group at 
10 min 
ROSC: ILE 5/5,  
EPI 4/5, 
Saline 2/5 
Yes 
Di Gregorio, 2009 
(92) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(20 mg/kg) 
2.68 Cardiac arrest 30%, 
Intralipid 
5 mL/kg 
(1.5 g/kg), 
repeated 
at 2.5 and 
5 min 
1 
mL/kg/min 
(18 g/kg/hr) 
ILE  
vs  
VASO  
vs  
VASO+EPI 
Other 
treatment and 
study treatment 
immediately 
after LA 
VASO 0.4 U/kg, 
EPI 30 g/kg, 
chest 
compression, 
mechanical 
ventilation 
Hemodynamics: Rate 
pressure product  higher in 
ILE vs VASO and VASO+EPI; 
QRS width: ILE group 
returned to baseline 
Survival: NR Yes; ILE resuscitation 
was superior to 
vasopressors (VASO 
and VASO+EPI) in 
treating bupivacaine-
induced asystole.  
Adverse events higher 
in vasopressor group 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Fettiplace, 2014  
(93) 
(Rats) 
RCS; 
resuscitation 
model 
Bupivacaine  
(10 mg/kg) 
2.68 Transient 
cardiovascular 
toxicity 
20% and 
30% 
Intralipid 
4 mL/kg 
(0.8 g/kg  
and 
1.2 g/kg) 
No 30% ILE  
vs  
20% ILE  
vs  
0.9% Saline  
vs  
Control (no 
treatment) 
Study 
treatment after 
10 sec 
Mechanical 
ventilation 
Time to 50% recovery of 
cardiovascular parameters 
rate-pressure product 
(RPP), MAP, Carotid flow 
(flow), HR; All animals 
returned to 50% RPP. Order 
of mean recovery times: 
ILE30<ILE20<Saline<Null.  
HR recovered faster than 
other measures 
parameters. 
Survival: ILE30 7/7,  
ILE20 7/7,  
Saline 7/7,  
Control 7/7 
Not studied 
Fettiplace, 2014 
(94) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg in 10 
sec) 
2.68 Asystole 30%, 
Intralipid 
IO 10 
mL/kg (3.0 
g/kg) in 
180 sec; IV 
10 mL/kg 
(3.0 g/kg)  
in 90 sec. 
0.5 
mL/kg/min 
(9 g/kg/hr) 
ILE (IO)  
vs  
ILE(IV)  
vs  
Saline (IO)  
 
Study 
treatment at 10 
sec. 
No Hemodynamics: ECG, aortic 
pressure, carotid blood 
flow; Return of 50% flow; 
Comparable recovery of 
hemodynamic variables in 
ILE (IO) and ILE (IV). Faster 
recovery in ILE (IO) and ILE 
(IV) compared to Saline and 
no treatment 
Survival: All Yes 
Gokahmetoglu, 
2014 (95) 
(Rabbit) 
RCS; 
resuscitation 
model 
Bupivacaine  
(10 mg/kg) 
2.68 Asystole 20% 
Intralipid 
1.5 mL/kg 
(0.3 g/kg), 
additional 
bolus x3, 5 
min 
interval if 
absense of 
ROSC 
0.25  
mL/kg/min 
(3 g/kg/hr), 
increased if 
absense of 
ROSC after 
additional 
boluses 
ILE  
vs  
Levosimendan 3 
mcg/kg/min  
vs  
ILE+Levosimendan 
3 mcg/kg/min 
vs 
0.9% Saline  
30 sec non-
intervention 
period, then 
study treatment  
Mechanical 
ventilation, 
manual chest 
compression, 
EPI 100 mcg/kg 
every 5 min 
Time to ROSC, min: Saline 
NA, ILE 7, Levosimendan 
10, ILE+Levosimendan 2. 
Arrests while alive, 
number : Saline NA, ILE 1, 
Levosimendan 1, 
ILE+Levosimendan 2. 
Duration of arrest , min : 
Saline 20, ILE 7.5, 
Levosimendan 20, 
ILE+Levosimendan 4 
ROSC: ILE 8/12, 
Levosimendan 
4/12, 
ILE+Levosimendan 
11/12,  
Saline 0/12 
No; Suggest prefered 
coadministration of 
EPI+ILE+Levosimendan 
compared to EPI+ILE or 
Levosimendan+EPI 
Hicks, 2009 (96) 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg in 10 
sec) 
2.68 Cardiac arrest, 
then wide QRS 
complex, 
premature 
ventricular 
contractions, and 
premature atrial 
contractions 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
ILE  
vs  
Saline 
Other 
treatments 
immediately 
after LA for 5 
min., then 
study treatment 
EPI (100  g/kg) 
and VASO (1.5 
U/kg) 
cardiac 
resuscitation 
Hemodynamics: MAP: 82.9 
+/-  12.2 (base line), 83.9 
+/-  10.4 (15 min), 83.6 +/-  
8.9 (30 min), 80.2  +/- 13.7  
(45 min), 69.5  +/- 7.8 (60 
min) 
Survival: ILE 3/10,  
Saline 4/9 
No; Adding ILE 
resuscitation to EPI and 
VASO did not improve 
outcomes 
4 
AACT manuscript LA to edit for CTX 
 
 
Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Hiller, 2009 (97) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(20 mg/kg) 
2.68 Asystole 30%, 
Intralipid 
5 mL/kg 
(1.5 g/kg) 
x2 
1 mL/kg (9 
g/kg/hr) for 
2 min 
ILE  
vs  
ILE+EPI  
vs  
Saline  
 
 
Other 
treatment 
immediately 
after LA, study 
treatment at 3 
min. 
Saline or ILE or 
ILE+EPI 1, 2.5, 
10 or 25 
mcg/kg. 
 
Hemodynamics: Manual 
chest compressions to 
achieve a rate-pressure 
product (=systolic pressure 
* HR) of at least 50% of 
baseline; 
EPI (up to 2.5 mcg/kg) 
improved initial ROSC but 
few animals sustained by 
15 min. ILE alone resulted 
in slower but more 
sustained recovery. 
Survival: All No; ILE alone 
compared to ILE+EPI 
(1, 2.5, 10, 25 mcg/kg). 
ILE alone resulted in 
ROSC, ILE+EPI doses 
below 10 had faster 
and more sustained 
ROSC 
Karci, 2009 (98) ¤ 
(Rats) 
RCS;  
resuscitation 
model 
Levobupivacaine  
(3 mg/kg/min) 
2.68 Decrease of 50% 
in mean BP. 
Asystole 
20%, 
brand NR 
No 1.5 mL/kg 
(0.6 
g/kg/hr) for 
30 min (one 
group) time 
NR for other 
groups  
Post-treatment ILE 
or Simultaneous-
treatment ILE  
vs 
no ILE 
vs 
No LA+ILE 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
Standard 
resuscitation 
(unspecified) 
Hemodynamics:  
No hemodynamic changes 
were observed in rats 
receiving only ILE emulsion; 
Time to development of 
asystole was longer 
compared to other 
levobupivacaine dosed 
groups. 
Survival: ILE at 50% 
MAP+std resusc 4 
/7,  
ILE+std resusc  1/7,  
std resusc 0/7,  
No LA+ILE 7/7 
Yes; Simultaneous 
treatment and post 
treatment parts 
suggest that 
administration of ILE 
may prevent cardiac 
arrest and ILE infusion 
along with standard 
resuscitation in cardiac 
arrest may improve 
survival 
Karcioglu, 2014 (99) 
(Rabbit) 
RCS; 
resuscitation 
model 
Levobupivacaine 
(10 mg/kg) 
2.68 Asystole 20% 
Intralipid 
1.5 mL/kg 
(0.3 g/kg),  
additional 
boluses, 5 
min 
interval if 
absebse of 
ROSC 
No ILE  
vs  
Saline 
30 sec non-
intervention 
period, then 
study treatment  
Mechanical 
ventilation, 
manual chest 
compression, 
EPI 100 mcg/kg 
every 5 min 
ROSC (MAP >50 mmHg and 
HR>120 bpm): ILE>Saline. 
Survival : ILE 3/7,  
Saline 1/7 
Not studied; ILE+EPI 
superior to EPI alone. 
Li, 2011 (100) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(20 mg/kg) 
2.68 Cardiac arrest 20%, 
Lipovenos 
MCT and 
Intralipid 
5 mL/kg (1 
g/kg) 
1 
mL/kg/min 
(12 g/kg/hr)  
for 3 min 
MCT/LCT ILE  
vs  
LCT ILE 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
EPI 40 mcg/kg 
(LCT), 50 
mcg/kg 
(MCT/LCT), 
chest 
compression, 
mechanical 
ventilation 
 
Hemodynamics: RPP more 
than 20% of baseline value 
for 1 min = ROSC 
Mortality after 
resusc lower in LCT 
(2/30) vs MCT/LCT 
(8/30) 
Not studied; Supports 
LCT over a MCT/LCT.  
Did not have a control 
without ILE 
resuscitation  
5 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Litonius, 2012 (101) 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine  
(2 mg/kg/min) or  
Mepivacaine 
(6 mg/kg/min) 
 
2.68 MAP decreased 
to 50% of its 
baseline value 
20%, 
ClinOleic 
and 
Intralipid 
1.5 mL/kg 
(0.3 g/kg) 
0.25 mL/kg 
/min (3 
g/kg/hr) for 
29 min 
ILE  
vs  
Ringer acetate 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
EPI 0.5 mg 
repeated 
doses, chest 
compression, 
mechanical 
ventilation, 
electrical 
defibrillation. 
Hemodynamics: 
Comparison of MAP and HR 
among treatment groups at 
each measured time point 
revealed no overall effect 
of ILE in comparison with 
Ringer’s acetate solution; 
No difference in effect 
between the two ILE’s 
tested 
Survival: Bupi+ILE 
10/10,  
Bupi+Ringer 8/10, 
Mepi+ILE 9/10, 
Mepi+Ringer 10/10 
 
No; ILEs did not 
improve hemodynamic 
parameters  
Mauch, 2012 (102) 
(Pig) 
RCS;  
compared ILE 
effect with EPI 
and vasopressin 
Bupivacaine  
(1 mg/kg/min) 
2.68 Cardiac arrest 20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
No ILE  
vs  
ILE+EPI  
vs 
ILE+VASO 
vs  
EPI 
 
Other 
treatment 
immediately 
after LA, study 
treatment at 1 
min. 
Vasopressors 
2IU, EPI 10 
ug/kg 
chest 
compression 
ROSC was regained after 
one EPI rescue dose in EPI 
and EPI+ILE. 
ILE and VASO+ILE ROSC 
achieved after secondary 
EPI rescue dose 
Survival: ILE 2/7, 
 ILE+EPI 6/7 
ILE+VASO 4/7,  
EPI 5/7 
No; Supports using EPI 
and EPI+ILE 
resuscitation over ILE 
resuscitation alone and 
ILE+VASO 
Mauch, 2011 (103) 
(Pig) 
RCS;  
compare 
effectiveness of 
EPI and ILE 
Bupivacaine 
(1 mg/kg/min 
until symptoms) 
2.68 LA infused at a 
rate of 1 
mg/kg*min until 
invasively 
measured MAP 
dropped to 50% 
of the initial 
value 
20%, 
Intralipid 
2 mL/kg 
(0.4 g/kg) 
and  
4 mL/kg 
(0.8 g/kg) 
No ILE 2 ml/kg 
vs 
ILE 4 ml/kg 
vs  
EPI 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
EPI rescue 
doses, 3 
mcg/kg, every 
5 min if 
MAP<75%. 
 
Hemodynamics : 
EPI bolus+resusc – HR 
(beats/min): baseline 127 
(101-154), 6-7 pigs reached 
baseline at t1-5 min. MAP 
(mmHg): baseline 51 (48-
52), 6-7 pigs reached 
baseline at t1-5 min. 
ILE 2+EPI resusc – HR 
(beats/min): baseline 122 
(107-130), 1 pig reached 
baseline at t4-5 min. MAP 
(mmHg): baseline 50 (48-
52), 1 pig reached baseline 
at t5 min. 
ILE 4+EPI resusc – HR 
(beats/min): baseline 113 
(107-142), 1 pig reached 
baseline at t5 min. MAP 
(mmHg): baseline 51 (50-
54), 3-4 pigs reached 
baseline at t4-5 min. 
Survival: ILE 2+EPI 
resusc 4/7,  
ILE 4+EPI resusc 
4/7, 
EPI bolus+resusc 
7/7, 
Yes; But EPI may be 
better first line therapy 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Mauch, 2011  
(104) ¤ 
(Pig) 
RCS;  
resuscitation 
model 
Bupivacaine 
(1 mg/kg/min 
until symptoms) 
2.68 Pulseless 
electrical activity, 
n=23 
Asystole, n=2. 
LA infused until 
cardiac arrest 
(pulseless 
electrical activity 
was defined as 
MAP 25% of 
initial value, 
corresponding to 
12-13 mmHg). 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
No ILE 
vs 
EPI 
vs 
ILE+EPI 
vs 
ILE+VASO 
 
 
Other 
treatment 
immediately 
after LA, study 
treatment at 1 
min. 
EPI bolus 10 
mcg/kg. 
Followed by 
rescue doses 
every 5 min if 
necessary, 10 
mcg/kg in case 
of cardiac 
arrest, or 3 
mcg/kg if 
MAP≤75%, 
chest 
compressions, 
mechanical 
ventilation 
Hemodynamics: EPI+std 
resusc - Secondary high 
dose EPI was not needed in 
surviving pigs; low dose EPI 
for haemodynamic support 
was given in 3 of 5 
surviving pigs; 
ILE - Secondary high dose 
EPI was needed in all 
surviving pigs;  low dose EPI 
for haemodynamic support 
was given in 1 surviving pig; 
ILE+EPI - Secondary high 
dose EPI was not needed in 
surviving pigs; 
ILE+VASO - Secondary high 
dose EPI was needed in all 
surviving pigs 
Survival:ILE 1/6,  
EPI 5/7, 
ILE+EPI  5/6, 
ILE+VASO 3/6 
No; EPI and EPI+ILE 
resuscitation was 
superior to ILE alone  
Mayr, 2008 (105) 
(Pig) 
RCS;  
compare  
resuscitation 
with ILE and 
VASO/EPI 
Bupivacaine 
(5 mg/kg) 
2.68 Aortic blood 
pressure 
decreasing to 
hydrostatic 
pressure; 
Asystole 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
for 10 min 
ILE  
vs  
VASO+EPI 
 
 
Other 
treatment at 1 
min., study 
treatment at 2 
min. 
Ringer’s 
solution, 
gelatin 
solution, saline 
(one group); 
VASO, EPI 
(saline group); 
Azaperone 4 
mg/kg IM, 
atropine 0.1 
mg/kg IM;  
Anesthesia, 
ketamine 20 
mg/kg IM, 
piritramid 30 
mg IV, 
maintained 
with isoflurane 
1-2% end-tidal; 
Heparin; 
Oxygen 
Hemodynamics: 
ILE+Saline - none of the ILE-
pigs had restoration of 
spontaneous circulation, 
coronary perfusion 
pressure <20-30 mmHg. 
EPI+VASO+Saline - 
coronary perfusion 
pressure as a decisive 
predictor of spontaneous 
circulation was significantly 
higher  90 s after the first 
and second VASO/EPI 
injection compared to ILE, 
>20-30 mmHg 
Survival: ILE+Saline 
0/5, 
EPI+VASO+Saline 
5/5 
No; Supports use of 
Vasopressors+EPI over 
ILE resuscitation 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Shi, 2003 (106) 
(Rats) 
RCS; 
Evaluation of the 
effect on 
hemodynamics 
and LA 
pharmacokinetics 
Bupivacaine 
(2 mg/kg/min for 
4 min) 
2.68 Hypotension, 
bradycardia 
30%, 
Intralipid 
No 3 ml/kg/min 
(54 g/kg/hr 
for 5 min) 
ILE 
Vs 
Saline 
Study 
treatment or 
other treatment 
immediately 
after LA 
No HR, MAP: Comparable 
Plasma-bupivacaine: 
distribution constant, 
elimination half-life(t½β) 
decreased in ILE groups, 
elimination half-life(t½α), 
clearance increased in ILE 
groups. 
Bupivacaine tissue (brain, 
myocytes, lung, kidney, 
spleen, muscle) content 
reduced in ILE group; 
increased in liver ILE group 
compared to saline 
Survival: All Yes; ILE accelerated the 
elimination of 
bupivacaine. The lipid 
sink phenomenon was 
observed. 
Wat, 2009 (107) ¤ 
(Pig) 
RCS;  
resuscitation 
model 
Ropivacaine 
(14.9±2.8 mg/kg) 
4.21 Cardiovascular 
collapse 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
ILE  
vs  
EPI  
vs  
Saline 
 
Other 
treatment 
immediately, 
study treatment 
NR 
Cardiac 
massage 
Failed to regain 50% of 
baseline systolic blood 
pressure and HR 10 min 
after iv treatment 
commenced. 
myocardial ATP content 
were not different between 
groups 
Survival: ILE 0/5,  
Epi 5/5, 
Saline 0/5 
No; Ropivacaine 
induced cardiac toxicity 
responded well to 
standard resuscitation 
with cardiac massage 
and intravenous 
adrenaline 
Weinberg, 2004 
(108) 
(Dogs) 
RCS;  
evaluation of the 
effect of 
bupivacaine on 
myocardial 
acidosis induced 
by ventricular 
fibrillation 
Bupivacaine 
(10 mg/kg) 
2.68 Ventricular 
fibrillation or 
myocardial pH 
7.0 
20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
for 10 min 
LA+ILE  
vs  
Saline+Fibrillation 
(no LA, fibrillation 
until same 
symptoms as LA 
group) 
 
Defibrillation at 
20 min or at 
myocardial 
pH≤7.0 
Fibrillation in 
non-ILE group 
PmO2 was comparable in 
saline vs LA+ILE group; 
Tissue pH decreased 4 
times faster in saline 
compared to LA group 
during ventricular 
fibrillation; 
Time to normal sinus 
rhythm was comparable in 
Saline vs LA+ILE group 
Survival: LA+ILE 
8/8,  
Saline 8/8 
Not studied 
Weinberg, 2003 
(109) 
(Dogs) 
RCS;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg in 10 
sec) 
2.68 Cardiac arrest 20%, 
Intralipid 
4 mL/kg 
(0.8 g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
for 10 min 
ILE  
vs  
Saline 
 
Other 
treatment 
immediately, 
study treatment 
at 10 min. 
Mechanical 
ventilation, 
internal cardiac 
massage 
Hemodynamics: PmO2, and 
pHm were improved during 
resuscitation with ILE 
compared with saline 
treatment in which dogs 
did not recover. Data are 
compared between 
baseline and after recovery 
Survival: ILE 6/6,  
Saline 0/6 
Yes 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Weinberg, 2008 
(110) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(20 mg/kg) 
2.68 Asystole 30%, 
Intralipid 
5 mL/kg 
(1.5 g/kg) 
0.5 
mL/kg/min 
(9 g/kg/hr) 
ILE  
vs  
EPI  
vs  
Saline 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
Chest 
compressions,  
mechanical 
ventilation 
QRS width:  
ILE – comparative 
EPI – Significantly 
prolonged at 2.5 min 
compared to ILE; But 
shorter than saline control. 
recovered to baseline at 5 
min. 
Saline – Significantly 
prolonged at 2.5 min 
compared to ILE, stayed 
elevated throughout the 
experiment 
Survival: ILE 5/5,  
EPI 5/5,  
Saline 5/5 
Yes   
Yan, 2012 (111) 
(Rats) 
RCS;  
resuscitation 
model 
Bupivacaine 
(30 mg/kg) 
2.68 Asystole 20%, 
Intralipid 
5 mL/kg (1 
g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
ILE  
vs  
ILE+EPI  
vs  
EPI  
vs  
Saline 
Other 
treatment 
immediately, 
study treatment 
at 10 min. 
No Hemodynamic parameters 
at 25min., coronary 
perfusion. Post-mortem 
myocardial LA content 
Survival: ILE 3/8,  
EPI+ILE 5/8,  
EPI 2/8, 
Saline 0/8, 
No; EPI+ILE had 
improved 
hemodynamics 
compared to ILE alone 
Yoshimoto 2014 
(112) ¤ 
(Rats) 
RCS; 
resuscitation 
model 
Bupivacaine 
(hyperbaric, 2 
mg/kg/min) 
2.68 Cardiac arrest 20%, 
brand NR 
5 mL/kg (1 
g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
ILE  
vs  
Saline 
CPR, then study 
treatment 
Glucose with 
LA. Immediate 
ventilation and 
chest 
compressions 
MAP and HR values at 2, 3, 
4, 5 and 10  min: ILE=Saline 
Survival rate 
unclear 
No; Suggests glucose 
reduces the ILE effect 
on reversal of LA-
induced cardiac arrest 
Observational              
Callejo, 2014 (113) 
¤ 
(Pig) 
Observational; 
compare ILE with 
saline 
Bupivacaine  
(4 mg/kg) 
2.68 150% increase in 
QRS duration 
Conc. NR, 
Intralipid 
1.5 mL/kg 0.25 
mL/kg/min 
ILE  
vs  
Saline 
NR NR QRS widening was reversed 
after ILE 
Survival NR. ILE: 
?/6, Saline ?/3 
No; Suggests 
concomitant 
resuscitation measures 
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Cave, 2010 (114) 
(Rabbit) 
Observational; 
compared to 21% 
saline 
Bupivacaine 
(10 mg/kg) 
2.68 Asystole 20%, 
Intralipid 
1.5 mL/kg 
(0.3 g/kg) 
0.25 
mL/kg/min 
(3 g/kg/hr) 
ILE  
vs 
ILE+Hypertonic 
saline (21%) 
Other 
treatment at 30 
sec., study 
treatment at 1 
min. 
Hypertonic 
saline (one 
group); 
Adrenaline 
ketamine 
Chest 
compressions 
and mechanical 
ventilation, 
with 100% 
oxygen. 
Hemodynamics: 
ILE+saline – Return of 
spontaneous circulation in 
9/10 animals in median 
(IQR [range]) time 2.5 (2.0-
5.0 [1.0-6.0]) min (No 
difference between 
groups); Number of 
adrenaline doses 1.5 (1.0-
3.0 [1-4]) (No difference 
between groups) 
ILE – Return of 
spontaneous circulation in 
7/10 animals  in median 
(IQR [range]) time 2.0 (2.0-
3.0 [2.0-3.0]) min (No 
difference between 
groups); Number of 
adrenaline doses 2.5 (1.8-
3.0 [1-4]) (No difference 
between groups) 
QRS width: 
ILE+saline - QRS duration at 
4 min 0.10 ms, 9 min 0.090 
ms, 14 min 0.095 ms, 19 
min 0.090 ms 
ILE – QRS duration 
significant longer at 4 min 
and 9 min; QRS duration at 
4 min 0.19 ms, 9 min 0.18 
ms, 14 min 0.095 ms, 19 
min 0.090 ms 
Survival: ILE 5/10, 
ILE+21% saline 
6/10,  
Not studied 
Weinberg, 1998 
(115) 
(Rats) 
Observational; 
resuscitation 
model 
Bupivacaine 
(various dose) 
2.68 Asystole 30%, 
Intralipid 
7.5 ml/kg 
(2.25 g/kg)  
3 
mL/kg/min 
(54 g/kg/hr)  
for 2 min 
Total dose 4 
g/kg 
ILE  
vs  
Saline 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
Bicarbonate: 2 
min 
IV fluids: 2.5 
min 
Vasopressors: 
3.05 g/kg 
ILE increased the dose 
required to cause death in 
50 % of animals 
LD50 study Yes; Increase LD50 
dose from 12.5 to 18.5 
mg/kg 
Case Series              
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
Harvey, 2010  
(116) 
(Rabbit) 
Case series;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg) 
2.68 Asystole 20%, 
Intralipid 
5 mL/kg (1 
g/kg) x2 
No ILE  
vs  
ILE+EPI 
 
Other 
treatment at 30 
sec., study 
treatment at 1 
min. 
Control group 
received late 
dosing of EPI 
100 mcg/kg (1 
mL/kg) 
Hemodynamics: Time to 
ROSC after chest 
compressions and 
mechanical ventilation. 
High-dose EPI 
administration was 
associated with a 
significant increase in 
coronary perfusion 
pressure before ROSC 
Survival: None; 
Failure of animals 
from any group to 
maintain effective 
circulation 
No; ILE alone was 
compared to ILE with 3 
doses of EPI. Only high 
dose EPI+ILE had ROSC 
Partownavid 2012 
(p.2431)  (117) 
(Rats) 
Case series;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg) 
2.68 Asystole NR 5 mL/kg 0.5 
mL/kg/min 
ILE  
vs  
Pre-treatment+ILE 
 
Other 
treatment 
immediately 
Pre-treatment 
with naloxone  
1 mg/kg,  
10 mcg/kg,  
5 mcg/kg,  
1 mcg/kg 
HR, ejection fraction and 
fractional shortening 
measures by ECG at 
baseline, 1, 5, 10 min.  
Survival rate 
unclear 
Not studied; Naloxone 
abolishes ILE rescue of 
bupivacaine-induced 
cardiotoxicity in a dose 
dependent manner 
Partownavid 2010 
(118)¤ 
(Rats) 
Case series;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg) 
2.68 Asystole 20%, 
Intralipid 
5 mL/kg (1 
g/kg) 
0.5 
mL/kg/min 
(6 g/kg/hr) 
ILE  
vs  
Pre-treatment+ILE 
 
Other 
treatment 
immediately 
Cardiac 
massage (LA 
groups); 
Fatty-acid 
oxidation 
inhibitor CVT 
(one group); 
Phosphate 
buffered saline 
(one group) 
Oxygen consumption, 
membrane potential and 
calcium-retention capacity 
(in response to Ca2+ 
overload) 
Survival rate 
unclear 
Not studied; Fatty-acid 
oxidation is required 
for successful rescue of 
bupivacaine-induced 
cardiotoxicity by ILE 
Partownavid 2012 
(119) ¤ 
(Rats) 
Case series;  
resuscitation 
model 
Bupivacaine 
(10 mg/kg) 
2.68 Asystole NR 5 mL/kg 0.5 
mL/kg/min 
ILE  
vs  
Pre-treatment+ILE 
 
Other 
treatment 
immediately 
Pre-treatment 
with fatty-acid 
oxidation 
inhibitor CVT 
(one group) 
 
HR, ejection fraction and 
fractional shortening 
measures by ECG at 
baseline, 1, 5, 10 min. 
Survival rate 
unclear 
Not studied; ILE rescue 
of bupivacaine-induced 
cardiotoxicity is 
abolished by fatty acid 
oxidation Inhibitor 
CVT-4325 
Yoshimoto, 2012 
(120) ¤(Rats) 
Case series; 
compared ILE 
effect between 2 
LA, no control 
Levobupivacaine  
(2 mg/kg/hr) 
or 
Ropivacaine  
(2 mg/kg/hr) 
2.68 
 
 
4.21 
Pulse pressure 
decrease to zero 
(0 mmHg, MAP 
6.8-7.6 ±1.3 
mmHg, HR 40-
47±15 bpm) 
30%, 
brand NR 
5 mL/kg 
(1.5 g/kg) 
0.5 
mL/kg/min 
(9 g/kg/hr) 
Levobupivacaine+ 
ILE  
vs  
Ropivacaine+ILE 
 
Other 
treatment and 
study treatment 
immediately 
after LA 
chest 
compressions 
and mechanical 
ventilation 
Hemodynamics: 
Levobupivacaine - HR at t5 
min 302±84; MAP (mmHg) 
at t2min 22±6, t3min 11±7, 
t4min 31±5, t5min 16±6, 
t10min 38±13;  
Ropivacaine - HR at t5 min 
152±75; MAP (mmHg) at 
t2min 16±5, t3min 54±32, 
t4min 16±4, t5min 184±15, 
t10min 77±60.  
Survival: 
Levobupi+ILE 6/6, 
Ropi+ILE 6/6 
Not studied 
Case report              
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Reference 
(Species) 
Model Local 
anesthetic 
(dose) 
Log 
D 
(129) 
Symptoms ILE 
used 
ILE 
bolus # 
ILE  
infusion 
# 
Study arms Timing of 
rescue, 
time from 
LA 
termination 
Other 
treatments 
received * 
Parameter 
measured 
Outcome Support 
therapeutic 
effect of ILE 
alone 
O'Brien, 2010 (121) 
(Cat) 
Case report Lidocaine 
(20 mg/kg) 
1.26 Lethargy, 
Erratic, poor-
quality pulses 
with severe 
hypotension, 
Almost cardiac 
arrest, 
Respiratory 
distress, 
pulmonary 
edema 
20%, 
Liposyn II 
No 1.5 mL/kg 
(0.6 
g/kg/hr) for 
30 min 
NA Other 
treatment 
immediately, 
ILE treatment at 
15 min. 
lactate ringer 
oxygen 
Hemodynamics: 
improvement in 
cardiovascular variables; 
CNS: Improvement in 
behavioral variables (more 
responsive to stimuli, could 
hold its head up without 
assistance). 
Survived Yes; 15 minutes after 
initiation of the ILE 
emulsion, the cat was 
more responsive to 
stimuli 
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Table 4 Summary estimates with associated GRADE ratings for human controlled 
studies reporting the effect of ILE on LA toxicity* 
 
*Summary estimate is expressed in difference between the “group intervention – group comparator”. Either a risk difference (RD), a mean 
difference (MD) or weighted mean difference (WMD) was reported. 
**Quality assessment according to the GRADE methodology. Of note, since no controlled studies were pooled together to answer a specific 
clinical question, inconsistency and publication bias were not evaluable. 
 
 
 
  
 Comparison Summary of Finding Quality of Evidence 
No of 
Studies 
Population 
Intervention 
(No of patients) 
Comparator 
(No of patients) 
Summary 
Estimate** 
Interpretation  Quality Assessment* 
GRADE 
Rating 
Cardiotoxicity 
N=1 
(11) 
 
Healthy 
volunteers 
receiving 
lidocaine infusion 
followed by either 
Ropivacaine or 
Levobupivacaine 
in continued 
infusion (8 
mg/min)  
20% Intralipid 
120 mL bolus 2 
min after the 
start of LA 
infusion (n=16 
for each LA 
infusion) 
Saline 
 
(n=16 for each 
LA infusion) 
Prolong QRS was 
present at the end of 
the LA infusion 
when compared 
with baseline, but no 
difference in PR, QTc 
or QRS duration 
between groups (P 
=0.68) 
No difference in 
EKG between 
groups.  
RCT cross-over; 
Downgrade: Indirectness 
due to surrogate marker 
(-1) and subclinical 
toxicity design (-1), 
Imprecision due to small 
sample size (-1) 
Very low 
Neurotoxicity 
N=1 
(11) 
Healthy 
volunteers 
receiving 
lidocaine infusion 
followed by either 
Ropivacaine or 
Levobupivacaine 
in continued 
infusion (8 
mg/min)  
20% Intralipid 
120 mL bolus 2 
min  after the 
start of LA 
infusion (n=16 
for each LA 
infusion) 
Saline 
 
(n=16 for each 
LA infusion) 
MD Ropivacaine = -
6.0 (-24.7; +12.7). 
MD Levobupivacaine 
= -11.4 (-32.4; 9.6). 
No EEG 
abnormalities 
observed. 
No difference in 
LA doses needed 
to reach 
neurotoxicity or in 
EEG changes 
between groups. 
RCT cross-over; 
Downgrade:  
Indirectness due to 
surrogate marker (-1) 
and subclinical toxicity 
design (-1), Imprecision 
due to small sample size 
(-1)  
Very low 
2 
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